BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260. [PMID: 11487534 DOI: 10.1053/gast.2001.26279] [Cited by in Crossref: 798] [Cited by in F6Publishing: 690] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Grimm MC. New and emerging therapies for inflammatory bowel diseases. Journal of Gastroenterology and Hepatology 2009;24:S69-74. [DOI: 10.1111/j.1440-1746.2009.06074.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
2 Auteri M, Zizzo MG, Serio R. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res 2015;93:11-21. [PMID: 25526825 DOI: 10.1016/j.phrs.2014.12.001] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 9.6] [Reference Citation Analysis]
3 Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients-A Pilot Uncontrolled Study. Am J Gastroenterology 2005;100:1370-5. [DOI: 10.1111/j.1572-0241.2005.41412.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
4 Veerappan SG, O’Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261-1272. [PMID: 21521250 DOI: 10.1111/j.1365-2036.2011.04667.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
5 Langgartner D, Füchsl AM, Uschold-Schmidt N, Slattery DA, Reber SO. Chronic subordinate colony housing paradigm: a mouse model to characterize the consequences of insufficient glucocorticoid signaling. Front Psychiatry 2015;6:18. [PMID: 25755645 DOI: 10.3389/fpsyt.2015.00018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
6 Pereira MS, Durães C, Catarino TA, Costa JL, Cleynen I, Novokmet M, Krištić J, Štambuk J, Conceição-Neto N, Machado JC, Marcos-Pinto R, Magro F, Vermeire S, Lauc G, Lago P, Pinho SS. Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis. Clin Transl Gastroenterol 2020;11:e00166. [PMID: 32352685 DOI: 10.14309/ctg.0000000000000166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
8 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
9 Rosh JR. Use of biologic agents in pediatric inflammatory bowel disease. Current Opinion in Pediatrics 2009;21:646-50. [DOI: 10.1097/mop.0b013e32832ff22c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Lattimer LDN, Chandler MB, Borum ML. Hispanics and Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:1214-8. [DOI: 10.1097/mib.0000000000000300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
11 Dodiuk-Gad RP, Ish-Shalom S, Shear NH. Systemic glucocorticoids: important issues and practical guidelines for the dermatologist. Int J Dermatol 2015;54:723-9. [PMID: 25683616 DOI: 10.1111/ijd.12642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: The price we have to pay?: . Inflammatory Bowel Diseases 2008;14:1019-21. [DOI: 10.1002/ibd.20407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
13 Ishiguro Y, Ohkawara T, Sakuraba H, Yamagata K, Hiraga H, Yamaguchi S, Fukuda S, Munakata A, Nakane A, Nishihira J. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin Immunol. 2006;120:335-341. [PMID: 16807115 DOI: 10.1016/j.clim.2006.05.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
14 Renga B, D’amore C, Cipriani S, Mencarelli A, Carino A, Sepe V, Zampella A, Distrutti E, Fiorucci S. FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. Pharmacological Research 2013;77:1-10. [DOI: 10.1016/j.phrs.2013.08.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rattigan R, O'Doherty JV, Vigors S, Ryan MT, Sebastiano RS, Callanan JJ, Thornton K, Rajauria G, Margassery LM, Dobson ADW, O'Leary ND, Sweeney T. The Effects of the Marine-Derived Polysaccharides Laminarin and Chitosan on Aspects of Colonic Health in Pigs Challenged with Dextran Sodium Sulphate. Mar Drugs 2020;18:E262. [PMID: 32429425 DOI: 10.3390/md18050262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Review of Gastroenterology & Hepatology 2014;2:23-34. [DOI: 10.1586/17474124.2.1.23] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
17 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
18 Prakash S, Urbanska AM. Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. Biologics 2008;2:355-78. [PMID: 19707368 DOI: 10.2147/btt.s2372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Dalal RS, Osterman MT, Buchner AM, Praestgaard A, Lewis JD, Lichtenstein GR. A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2019;25:1550-8. [DOI: 10.1093/ibd/izz014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Shastri S, Shinde T, Woolley KL, Smith JA, Gueven N, Eri R. Short-Chain Naphthoquinone Protects Against Both Acute and Spontaneous Chronic Murine Colitis by Alleviating Inflammatory Responses. Front Pharmacol 2021;12:709973. [PMID: 34497514 DOI: 10.3389/fphar.2021.709973] [Reference Citation Analysis]
21 Zhao Y, Guo Q, Zhu Q, Tan R, Bai D, Bu X, Lin B, Zhao K, Pan C, Chen H, Lu N. Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress. Mucosal Immunol 2019;12:1150-63. [DOI: 10.1038/s41385-019-0177-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
22 Wolters FL, Joling C, Russel MG, Sijbrandij J, De Bruin M, Odes S, Riis L, Munkholm P, Bodini P, Ryan B. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol. 2007;42:333-344. [PMID: 17354113 DOI: 10.1080/00365520600930750] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
23 Bossa F, Colombo E, Andriulli A, Annese V. Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy 2009;10:1449-60. [DOI: 10.1517/14656560902973728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Zhang L, Wei X, Zhang R, Petitte JN, Si D, Li Z, Cheng J, Du M. Design and Development of a Novel Peptide for Treating Intestinal Inflammation. Front Immunol 2019;10:1841. [PMID: 31447849 DOI: 10.3389/fimmu.2019.01841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
25 Rubin DT. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol. 2011;9:456-457. [PMID: 21421077 DOI: 10.1016/j.cgh.2011.03.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
26 Leoncini G, Villanacci V, Marin MG, Crisafulli V, Cadei M, Antonelli E, Leoci C, Bassotti G. Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. Tech Coloproctol. 2018;22:941-946. [PMID: 30535522 DOI: 10.1007/s10151-018-1896-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
27 Gionchetti P, Calabrese C, Tambasco R, Brugnera R, Straforini G, Liguori G, Fornarini GS, Riso D, Campieri M, Rizzello F. Role of conventional therapies in the era of biological treatment in Crohn’s disease. World J Gastroenterol 2011; 17(14): 1797-1806 [PMID: 21528051 DOI: 10.3748/wjg.v17.i14.1797] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
28 Nakamura T, Nagahori M, Kanai T, Watanabe M. Current Pharmacologic Therapies and Emerging Alternatives in the Treatment of Ulcerative Colitis. Digestion 2008;77:36-41. [DOI: 10.1159/000111486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. 2006;101:110-118. [PMID: 16405542 DOI: 10.1111/j.1572-0241.2006.00330.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
30 Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447. [PMID: 18848556 DOI: 10.1053/j.gastro.2008.09.053] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
31 An YK. Common mistakes with steroids. J Gastroenterol Hepatol 2021;36 Suppl 1:30-1. [PMID: 33817842 DOI: 10.1111/jgh.15458] [Reference Citation Analysis]
32 Yao W, Yang C, Wen Y, Zhang W, Zhang X, Ma Q, Ji P, Hua Y, Wei Y. Treatment effects and mechanisms of Yujin Powder on rat model of large intestine dampness-heat syndrome. J Ethnopharmacol 2017;202:265-80. [PMID: 28330724 DOI: 10.1016/j.jep.2017.03.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
33 Bertani L, Bodini G, Mumolo MG, de Bortoli N, Ceccarelli L, Frazzoni L, Tapete G, Albano E, Plaz Torres MC, Bellini M, Savarino E, Savarino V, Marchi S, Costa F. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Dig Dis Sci 2020;65:2397-402. [DOI: 10.1007/s10620-019-05959-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol. 2006;101:1048-1056. [PMID: 16573777 DOI: 10.1111/j.1572-0241.2006.00524.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 110] [Article Influence: 7.9] [Reference Citation Analysis]
35 Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008;27:228-40. [PMID: 17988236 DOI: 10.1111/j.1365-2036.2007.03569.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
36 Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17:1549-1559. [PMID: 27157244 DOI: 10.1080/14656566.2016.1183648] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
37 Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
38 Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
39 Cross RK, Cheevers N, Finkelstein J. Home telemanagement for patients with ulcerative colitis (UC HAT). Dig Dis Sci. 2009;54:2463-2472. [PMID: 19104937 DOI: 10.1007/s10620-008-0640-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
40 Sengupta M, Cheema A, Kaminski HJ, Kusner LL; Muscle Study Group. Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment. PLoS One 2014;9:e102635. [PMID: 25032816 DOI: 10.1371/journal.pone.0102635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
41 Lightner AL, Pemberton JH. The Role of Temporary Fecal Diversion. Clin Colon Rectal Surg. 2017;30:178-183. [PMID: 28684935 DOI: 10.1055/s-0037-1598158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
42 Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115-133. [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
43 Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients: Review: communicating risks of IBD therapy. Alimentary Pharmacology & Therapeutics 2011;33:23-32. [DOI: 10.1111/j.1365-2036.2010.04489.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
44 Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid-Dependent Crohnʼs Disease: . Inflammatory Bowel Diseases 2009;15:375-82. [DOI: 10.1002/ibd.20777] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 8.1] [Reference Citation Analysis]
45 Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60. [PMID: 11856078 DOI: 10.1046/j.1365-2036.2002.01140.x] [Cited by in Crossref: 310] [Cited by in F6Publishing: 277] [Article Influence: 15.5] [Reference Citation Analysis]
46 Einwächter H. Current Concepts of Pharmacotherapy in Crohn's Disease. Visc Med 2019;35:344-7. [PMID: 31934581 DOI: 10.1159/000504101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Gisbert JP, Niño P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28:228-38. [PMID: 18485129 DOI: 10.1111/j.1365-2036.2008.03732.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
48 Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J. [Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:511-516. [PMID: 17980127 DOI: 10.1157/13111681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
49 Castro M, Rossi L, Papadatou B, Bracci F, Knafelz D, Ambrosini M, Calce A, Serafini S, Isacchi G, D'orio F, Mambrini G, Magnani M. Long-term Treatment With Autologous Red Blood Cells Loaded With Dexamethasone 21–Phosphate in Pediatric Patients Affected by Steroid-dependent Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2007;44:423-6. [DOI: 10.1097/mpg.0b013e3180320667] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
50 Kruis W, Katalinic A, Klugmann T, Franke GR, Weismüller J, Leifeld L, Ceplis-Kastner S, Reimers B, Bokemeyer B. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohns Colitis 2013;7:e263-70. [PMID: 23182164 DOI: 10.1016/j.crohns.2012.10.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
51 Ewald PW, Swain Ewald HA. An evolutionary perspective on the causes and treatment of inflammatory bowel disease: . Current Opinion in Gastroenterology 2013;29:350-6. [DOI: 10.1097/mog.0b013e328361f80f] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Cohen RD. What is the optimal maintenance treatment for ulcerative colitis? Inflamm Bowel Dis. 2008;14 Suppl 2:S236-S237. [PMID: 18816679 DOI: 10.1002/ibd.20670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Obara Y, Komatsu M, Sugawara T. Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. Perm J 2019;23. [PMID: 31050638 DOI: 10.7812/TPP/18-220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:191-208, viii. [PMID: 15177534 DOI: 10.1016/j.gtc.2004.02.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
55 Olivares-Morales MJ, De La Fuente MK, Dubois-Camacho K, Parada D, Diaz-Jiménez D, Torres-Riquelme A, Xu X, Chamorro-Veloso N, Naves R, Gonzalez MJ, Quera R, Figueroa C, Cidlowski JA, Vidal RM, Hermoso MA. Glucocorticoids Impair Phagocytosis and Inflammatory Response Against Crohn's Disease-Associated Adherent-Invasive Escherichia coli. Front Immunol 2018;9:1026. [PMID: 29867993 DOI: 10.3389/fimmu.2018.01026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
56 Maranville JC, Micic D, Hanauer SB, Di Rienzo A, Kupfer SS. In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014;8:1539-1547. [PMID: 25052346 DOI: 10.1016/j.crohns.2014.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
57 Knyazev OV, Parfenov AI, Shcherbakov PL, Ruchkina IN, Konoplyannikov AG. Cell therapy of refractory Crohn's disease. Bull Exp Biol Med 2013;156:139-45. [PMID: 24319711 DOI: 10.1007/s10517-013-2297-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
58 Liu QQ, Wang HL, Chen K, Wang SB, Xu Y, Ye Q, Sun YW. Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B. J Dig Dis. 2016;17:104-112. [PMID: 26718746 DOI: 10.1111/1751-2980.12314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
59 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 256] [Article Influence: 16.1] [Reference Citation Analysis]
60 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006;24:1403-12. [PMID: 17081161 DOI: 10.1111/j.1365-2036.2006.03147.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
62 Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010;25:886-891. [PMID: 20546441 DOI: 10.1111/j.1440-1746.2009.06206.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
63 Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011;106:413-20. [PMID: 20717106 DOI: 10.1038/ajg.2010.317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
64 Flasar MH, Quezada S, Bijpuria P, Cross RK. Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study. Dig Dis Sci. 2008;53:2754-2760. [PMID: 18273704 DOI: 10.1007/s10620-007-0190-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
65 Schmidt C, Lautenschlaeger C, Collnot E, Schumann M, Bojarski C, Schulzke J, Lehr C, Stallmach A. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa—A first in vivo study in human patients. Journal of Controlled Release 2013;165:139-45. [DOI: 10.1016/j.jconrel.2012.10.019] [Cited by in Crossref: 130] [Cited by in F6Publishing: 123] [Article Influence: 14.4] [Reference Citation Analysis]
66 McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs. 2002;62:2263-2282. [PMID: 12381231 DOI: 10.2165/00003495-200262150-00015] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
67 Ahluwalia JP. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012;96:525-44. [DOI: 10.1016/j.mcna.2012.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
68 Turunen P, Ashorn M, Auvinen A, Iltanen S, Huhtala H, Kolho KL. Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2009;15:56-62. [PMID: 18623165 DOI: 10.1002/ibd.20558] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.7] [Reference Citation Analysis]
69 Romberg-Camps MJ, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MA, Kester AD, Engels LG, van Deursen C, Hameeteman WH, Pierik M, Wolters F. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis. 2010;16:2137-2147. [PMID: 20848468 DOI: 10.1002/ibd.21285] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 11.4] [Reference Citation Analysis]
70 Liu W, Guo W, Guo L, Gu Y, Cai P, Xie N, Yang X, Shu Y, Wu X, Sun Y, Xu Q. Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response. International Immunopharmacology 2014;20:337-45. [DOI: 10.1016/j.intimp.2014.03.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
71 Haller CA, Markowitz J. IBD in children: lessons for adults. Curr Gastroenterol Rep 2007;9:528-32. [PMID: 18377807 DOI: 10.1007/s11894-007-0070-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
72 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
73 Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
74 Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Filipe V, Allen PB, Peyrin-biroulet L. Self-medication with steroids in inflammatory bowel disease. Digestive and Liver Disease 2016;48:23-6. [DOI: 10.1016/j.dld.2015.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
76 Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006;23:1435-1442. [PMID: 16669958 DOI: 10.1111/j.1365-2036.2006.02904.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
77 Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am. 2004;33:171-189, vii. [PMID: 15177533 DOI: 10.1016/j.gtc.2004.02.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
78 Ribeiro TCDR, Chebli LA, Gaburri PD, Chebli JMF. Azathioprine in ulcerative colitis: Why, when, how and how long to use it. Drug Dev Res 2011;72:733-8. [DOI: 10.1002/ddr.20481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
80 Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterology Clinics of North America 2004;33:235-50. [DOI: 10.1016/j.gtc.2004.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
81 Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018;64:20-57. [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 88] [Article Influence: 21.6] [Reference Citation Analysis]
82 Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, Fritz P, Schwab M, Schaeffeler E. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011;89:422-428. [PMID: 21289623 DOI: 10.1038/clpt.2010.348] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
83 Scholmerich J. Inflammatory Bowel Disease: Pandora's Box, Present and Future. Annals of the New York Academy of Sciences 2006;1072:365-78. [DOI: 10.1196/annals.1326.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
84 Sachar DB. Management of acute, severe ulcerative colitis: Management of severe ulcerative colitis. Journal of Digestive Diseases 2012;13:65-8. [DOI: 10.1111/j.1751-2980.2011.00560.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Bernstein CN. The Natural History of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 343-63. [DOI: 10.1007/978-1-4614-0998-4_26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Reference Citation Analysis]
87 Cross RK, Finkelstein J. Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study. Dig Dis Sci 2007;52:357-64. [PMID: 17211702 DOI: 10.1007/s10620-006-9523-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
88 Koppes AN, Kamath M, Pfluger CA, Burkey DD, Dokmeci M, Wang L, Carrier RL. Complex, multi-scale small intestinal topography replicated in cellular growth substrates fabricated via chemical vapor deposition of Parylene C. Biofabrication 2016;8:035011. [PMID: 27550930 DOI: 10.1088/1758-5090/8/3/035011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
89 Palmieri O, Latiano A, Valvano R, D’Incà R, Vecchi M, Sturniolo GC, Saibeni S, Bossa F, Latiano T, Devoto M. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005;22:1129-1138. [PMID: 16305727 DOI: 10.1111/j.1365-2036.2005.02701.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
90 Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liver Dis 2005;37:973-9. [PMID: 16169305 DOI: 10.1016/j.dld.2005.07.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
91 Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, Colvin HS, Wato M, Ando M, Nakamura S, Mizobuchi K, Okada H. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 2021;21:325. [PMID: 34425765 DOI: 10.1186/s12876-021-01903-5] [Reference Citation Analysis]
92 Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744-753. [PMID: 16682258 DOI: 10.1016/j.cgh.2006.03.010] [Cited by in Crossref: 274] [Cited by in F6Publishing: 232] [Article Influence: 17.1] [Reference Citation Analysis]
93 Kim DH, Cheon JH, Park JJ, Yoon JY, Moon CM, Hong SP, Kim TI, Kim WH. Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn’s disease. Gut Liver. 2013;7:58-65. [PMID: 23423699 DOI: 10.5009/gnl.2013.7.1.58] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
94 Alrefai D, Jones J, El-Matary W, Whiting SJ, Aljebreen A, Mirhosseini N, Vatanparast H. The Association of Vitamin D Status with Disease Activity in a Cohort of Crohn's Disease Patients in Canada. Nutrients 2017;9:E1112. [PMID: 29023388 DOI: 10.3390/nu9101112] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
95 Lian L, Fazio VW, Hammel J, Shen B. Impact of narcotic use on the requirement for colectomy in inpatients with ulcerative colitis. Dis Colon Rectum 2010;53:1295-300. [PMID: 20706073 DOI: 10.1007/DCR.0b013e3181e7562c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
96 Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007;26:987-1003. [PMID: 17877506 DOI: 10.1111/j.1365-2036.2007.03455.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
97 Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-330. [PMID: 16842459 DOI: 10.1111/j.1365-2036.2006.02974.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 8.9] [Reference Citation Analysis]
98 Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005;11 Suppl 1:S3-S12. [PMID: 16254481 DOI: 10.1097/01.mib.0000184852.84558.b2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
99 Barahona-Garrido J, Camacho-Escobedo J, García-Martínez CI, Tocay H, Cabiedes J, Yamamoto-Furusho JK. Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1039-1043. [PMID: 19107779 DOI: 10.1002/ibd.20852] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
100 Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673-692. [PMID: 29132528 DOI: 10.1016/j.pop.2017.07.010] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 25.4] [Reference Citation Analysis]
101 Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin YC, Yang H. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53:1129-1136. [PMID: 15247180 DOI: 10.1136/gut.2003.036657] [Cited by in Crossref: 138] [Cited by in F6Publishing: 120] [Article Influence: 7.7] [Reference Citation Analysis]
102 Rubin DT, Patel H, Shi S, Mody R. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn’s disease in the United States: a claims data analysis. Current Medical Research and Opinion 2017;33:529-36. [DOI: 10.1080/03007995.2016.1267616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
103 Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35. [PMID: 16481629 DOI: 10.1136/gut.2005.081950b] [Cited by in Crossref: 423] [Cited by in F6Publishing: 365] [Article Influence: 26.4] [Reference Citation Analysis]
104 Shastri S, Shinde T, Perera AP, Gueven N, Eri R. Idebenone Protects against Spontaneous Chronic Murine Colitis by Alleviating Endoplasmic Reticulum Stress and Inflammatory Response. Biomedicines 2020;8:E384. [PMID: 32998266 DOI: 10.3390/biomedicines8100384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Huang EY, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, Musch MW, Theriault B, Higuchi K, Donovan S, Gilbert J, Chang EB. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:963-72. [PMID: 25738379 DOI: 10.1097/MIB.0000000000000332] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
106 Allenspach K, Rüfenacht S, Sauter S, Gröne A, Steffan J, Strehlau G, Gaschen F. Pharmacokinetics and Clinical Efficacy of Cyclosporine Treatment of Dogs with Steroid-Refractory Inflammatory Bowel Disease. Journal of Veterinary Internal Medicine 2006;20:239-44. [DOI: 10.1111/j.1939-1676.2006.tb02852.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
107 Thia KT, Li M, Ling KL, Kong SC, Ooi CJ. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:809-815. [PMID: 20645318 DOI: 10.1002/ibd.21382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
108 Yen CC, Chen YC, Wu MT, Wang CC, Wu YT. Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. Int J Nanomedicine 2018;13:669-80. [PMID: 29440893 DOI: 10.2147/IJN.S154824] [Cited by in Crossref: 47] [Cited by in F6Publishing: 15] [Article Influence: 11.8] [Reference Citation Analysis]
109 Afif W, Loftus EV. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009;38:691-709. [DOI: 10.1016/j.gtc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
110 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
111 Ogasawara N, Sasaki M, Hijikata Y, Masui R, Tanida S, Kanematsu T, Kamiya T, Kataoka H, Joh T, Kasugai K. Successful treatment for pouchitis with rebamipide refractory to a combination of metronidazole (MNZ) and ciprofloxacin (CFX). Clin J Gastroenterol 2009;2:404-7. [PMID: 26192795 DOI: 10.1007/s12328-009-0115-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Kim MJ, Choe YH. Change in the treatment strategy for pediatric Crohn's disease. Korean J Pediatr 2010;53:830-3. [PMID: 21189967 DOI: 10.3345/kjp.2010.53.9.830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
113 Feagan BG, Sandborn WJ, Lichtenstein G, Radford-smith G, Patel J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;23:617-28. [DOI: 10.1111/j.1365-2036.2006.02791.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
114 Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Med Clin North Am. 2010;94:35-52. [PMID: 19944797 DOI: 10.1016/j.mcna.2009.10.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
115 Kim C, Kovacs-nolan J, Yang C, Archbold T, Fan M, Mine Y. L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochimica et Biophysica Acta (BBA) - General Subjects 2009;1790:1161-9. [DOI: 10.1016/j.bbagen.2009.05.018] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 6.0] [Reference Citation Analysis]
116 Videla S, Vilaseca J, Medina C, Mourelle M, Guarner F, Salas A, Malagelada JR. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther. 2006;316:940-945. [PMID: 16254133 DOI: 10.1124/jpet.105.090837] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
117 Joo E, Yamane S, Hamasaki A, Harada N, Matsunaga T, Muraoka A, Suzuki K, Nasteska D, Fukushima T, Hayashi T, Tsuji H, Shide K, Tsuda K, Inagaki N. Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice. Nutrition 2013;29:549-55. [DOI: 10.1016/j.nut.2012.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
118 Lei H, Johnson LA, Eaton KA, Liu S, Ni J, Wang X, Higgins PDR, Xu G. Characterizing intestinal strictures of Crohn's disease in vivo by endoscopic photoacoustic imaging. Biomed Opt Express 2019;10:2542-55. [PMID: 31143502 DOI: 10.1364/BOE.10.002542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
119 Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn's disease in Japan. J Gastroenterol 2005;40 Suppl 16:25-31. [PMID: 15902960 DOI: 10.1007/BF02990575] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
120 Wu XW, Wu L, Ji HZ, Wang FY. Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis. Dig Dis Sci. 2015;60:3203-3208. [PMID: 26031424 DOI: 10.1007/s10620-015-3733-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
121 Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273 [PMID: 23345950 DOI: 10.3748/wjg.v19.i2.265] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
122 Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320-327. [PMID: 12891531 DOI: 10.1016/s0016-5085(03)00883-7] [Cited by in Crossref: 217] [Cited by in F6Publishing: 51] [Article Influence: 11.4] [Reference Citation Analysis]
123 Hundorfean G, Neurath MF, Sitaru C. Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med 2010;14:2393-403. [PMID: 19878366 DOI: 10.1111/j.1582-4934.2009.00959.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
124 Kannengiesser K, Maaser C, Kucharzik T. Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies. Per Med 2008;5:609-26. [PMID: 29788621 DOI: 10.2217/17410541.5.6.609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005;:CD000296. [PMID: 16235274 DOI: 10.1002/14651858.CD000296.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
126 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
127 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
128 Torres UDS, Satomi G, Ronchi LS, Netinho JG. Infliximabe na doença de crohn: experiência clínica de um centro terciário paulista. Rev bras colo-proctol 2009;29:38-45. [DOI: 10.1590/s0101-98802009000100005] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
129 Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan. Clinical Gastroenterology and Hepatology 2008;6:999-1003. [DOI: 10.1016/j.cgh.2008.05.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
130 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
131 Li S, Takasu C, Lau H, Robles L, Vo K, Farzaneh T, Vaziri ND, Stamos MJ, Ichii H. Dimethyl Fumarate Alleviates Dextran Sulfate Sodium-Induced Colitis, through the Activation of Nrf2-Mediated Antioxidant and Anti-inflammatory Pathways. Antioxidants (Basel) 2020;9:E354. [PMID: 32344663 DOI: 10.3390/antiox9040354] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
132 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
133 Bolge SC, Waters H, Piech CT. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey. Clin Ther. 2010;32:238-245. [PMID: 20206781 DOI: 10.1016/j.clinthera.2010.02.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
134 Yin P, Zou W, Li J, Jin N, Gao Q, Liu F. Using high-throughput sequencing to explore the anti-inflammatory effects of α-mangostin. Sci Rep 2019;9:15626. [PMID: 31666566 DOI: 10.1038/s41598-019-52036-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
135 Blonski W, Buchner AM, Lichtenstein GR. Treatment of ulcerative colitis. Curr Opin Gastroenterol. 2014;30:84-96. [PMID: 24285003 DOI: 10.1097/mog.0000000000000031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
136 Awaad AS, El-meligy RM, Soliman GA. Natural products in treatment of ulcerative colitis and peptic ulcer. Journal of Saudi Chemical Society 2013;17:101-24. [DOI: 10.1016/j.jscs.2012.03.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
137 Brito TV, Neto JP, Prudêncio RS, Batista JA, Júnior JS, Silva RO, Franco AX, Aragão KS, Soares PM, Souza MH, Chaves LS, Freitas AL, Medeiros JV, Barbosa AL. Sulfated-polysaccharide fraction extracted from red algae Gracilaria birdiae ameliorates trinitrobenzenesulfonic acid-induced colitis in rats. J Pharm Pharmacol 2014;66:1161-70. [PMID: 24579929 DOI: 10.1111/jphp.12231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
138 Wolters FL, Russel MG, Stockbrügger RW. Systematic review: has disease outcome in Crohn’s disease changed during the last four decades? Aliment Pharmacol Ther. 2004;20:483-496. [PMID: 15339320 DOI: 10.1111/j.1365-2036.2004.02123.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 4.4] [Reference Citation Analysis]
139 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Ghosh S. Management of Crohn’s disease from efficacy, quality of life and health economic perspectives. Expert Review of Pharmacoeconomics & Outcomes Research 2014;3:587-98. [DOI: 10.1586/14737167.3.5.587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
141 Modesto I, Scimeca D, Orlando A, Cottone M. Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: clinical response without endoscopic response. Inflamm Bowel Dis 2006;12:1009-10. [PMID: 17012976 DOI: 10.1097/01.mib.0000235098.24478.e0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Kawakami K, Inoue T, Murano M, Narabayashi K, Nouda S, Ishida K, Abe Y, Nogami K, Hida N, Yamagami H, Watanabe K, Umegaki E, Nakamura S, Arakawa T, Higuchi K. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015; 21(6): 1880-1886 [PMID: 25684955 DOI: 10.3748/wjg.v21.i6.1880] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
143 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072. [PMID: 23448790 DOI: 10.1097/mib.0b013e3182802909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
144 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
145 Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis: Combination therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177-85. [DOI: 10.1111/jgh.12517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
146 Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. [PMID: 12047962 DOI: 10.1016/s0140-6736(02)08512-4] [Cited by in Crossref: 2805] [Cited by in F6Publishing: 777] [Article Influence: 140.3] [Reference Citation Analysis]
147 Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis. 2008;40 Suppl 2:S247-S252. [PMID: 18598996 DOI: 10.1016/s1590-8658(08)60533-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
148 Jacobstein DA, Baldassano RN. Use of 6-Mercaptopurine/Azathioprine as the Immunomodulator of Choice for Moderately Active Crohnʼs Disease: Balance. Inflammatory Bowel Diseases 2005;11:203-5. [DOI: 10.1097/00054725-200502000-00016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
149 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008; 14(36): 5523-5527 [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
150 Tung K, Baker AC, Amini A, Green TL, Chew VW, Lim D, Nguyen ST, Yee KS, Cho K, Greenhalgh DG. Novel Hyperactive Glucocorticoid Receptor Isoform Identified Within a Human Population. Shock 2011;36:339-44. [DOI: 10.1097/shk.0b013e318228eca7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
151 George LA, Cross RK. Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). Gastroenterology Clinics of North America 2020;49:705-16. [DOI: 10.1016/j.gtc.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Lenti MV, Armuzzi A, Castiglione F, Fantini MC, Fiorino G, Orlando A, Pugliese D, Rizzello F, Vecchi M, Di Sabatino A. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. Digestive and Liver Disease 2020;52:44-50. [DOI: 10.1016/j.dld.2019.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
153 Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis 2009;15:1570-82. [PMID: 19309716 DOI: 10.1002/ibd.20918] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
154 Nightingale A. Diagnosis and management of inflammatory bowel disease. Nurse Prescribing 2007;5:289-96. [DOI: 10.12968/npre.2007.5.7.24413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Farrell RJ, Menconi MJ, Keates AC, Kelly CP. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol Ther. 2002;16:1021-1031. [PMID: 11966513 DOI: 10.1046/j.1365-2036.2002.01238.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
156 Krupoves A, Mack DR, Seidman EG, Deslandres C, Bucionis V, Amre DK. Immediate and long-term outcomes of corticosteroid therapy in pediatric Crohn's disease patients. Inflamm Bowel Dis 2011;17:954-62. [PMID: 20684012 DOI: 10.1002/ibd.21415] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
157 Sharma M, Kaur R, Kaushik K, Kaushal N. Redox modulatory protective effects of ω-3 fatty acids rich fish oil against experimental colitis. Toxicol Mech Methods 2019;29:244-54. [PMID: 30489199 DOI: 10.1080/15376516.2018.1553220] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
158 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
159 Ferrara G, Petrillo MG, Giani T, Marrani E, Filippeschi C, Oranges T, Simonini G, Cimaz R. Clinical Use and Molecular Action of Corticosteroids in the Pediatric Age. Int J Mol Sci 2019;20:E444. [PMID: 30669566 DOI: 10.3390/ijms20020444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
160 Cuffari C, Present DH, Bayless TM, Lichtenstein GR. Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis 2005;11:937-46. [PMID: 16189424 DOI: 10.1097/01.mib.0000179469.86500.ac] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
161 Lahad A, Weiss B. Current therapy of pediatric Crohn’s disease. World J Gastrointest Pathophysiol 2015; 6(2): 33-42 [PMID: 25977836 DOI: 10.4291/wjgp.v6.i2.33] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
162 Sud S, Sachdeva S, Puri AS. Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India. Indian J Gastroenterol 2021. [PMID: 34971402 DOI: 10.1007/s12664-021-01185-5] [Reference Citation Analysis]
163 Velayos FS, Sandborn WJ. Positioning biologic therapy for Crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2007;9:521-7. [DOI: 10.1007/s11894-007-0069-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
164 Koenecke C, Förster R. CCR9 and inflammatory bowel disease. Expert Opinion on Therapeutic Targets 2009;13:297-306. [DOI: 10.1517/14728220902762928] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
165 Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader J, Gonvers J, Froehlich F. Severe and Steroid-Resistant Crohn’s Disease. Digestion 2008;76:99-108. [DOI: 10.1159/000111023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
166 Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. American Journal of Gastroenterology 2017;112:325-36. [DOI: 10.1038/ajg.2016.524] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
167 Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007;9:513-20. [DOI: 10.1007/s11894-007-0068-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
168 Amre D, Amre R, Prakash S. Inflammatory bowel diseases: current treatment strategies and potential for drug delivery using artificial cell microcapsules. Artificial Cells, Cell Engineering and Therapy. Elsevier; 2007. pp. 454-68. [DOI: 10.1533/9781845693077.4.454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Flasar MH, Johnson T, Roghmann M, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study: . Inflammatory Bowel Diseases 2008;14:13-9. [DOI: 10.1002/ibd.20298] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
170 Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681-688.e1. [PMID: 24269926 DOI: 10.1053/j.gastro.2013.11.024] [Cited by in Crossref: 200] [Cited by in F6Publishing: 170] [Article Influence: 22.2] [Reference Citation Analysis]
171 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Reference Citation Analysis]
172 Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, Scoazec JY. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis. 2008;14:874-877. [PMID: 18275074 DOI: 10.1002/ibd.20395] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
173 Okayasu M, Ogata H, Yoshiyama Y. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. J Mark Access Health Policy 2019;7:1565889. [PMID: 30719244 DOI: 10.1080/20016689.2019.1565889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
174 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
175 Saito K, Katsuno T, Nakagawa T, Saito M, Sazuka S, Sato T, Matsumura T, Arai M, Miyauchi H, Matsubara H, Yokosuka O. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther 2012;36:744-54. [DOI: 10.1111/apt.12033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
176 Truffinet O, Martinez-vinson C, Guerriero E, Hugot J, Viala J. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. Journal of Pediatric Gastroenterology & Nutrition 2017;64:721-5. [DOI: 10.1097/mpg.0000000000001338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
177 Parente F, Molteni M, Marino B, Colli A, Ardizzone S, Greco S, Sampietro G, Foschi D, Gallus S. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis? Am J Gastroenterol. 2010;105:1150-1157. [PMID: 19997096 DOI: 10.1038/ajg.2009.672] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
178 Tamboli CP, Caucheteux C, Cortot A, Colombel J, Desreumaux P. Probiotics in inflammatory bowel disease: a critical review. Best Practice & Research Clinical Gastroenterology 2003;17:805-20. [DOI: 10.1016/s1521-6918(03)00076-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
179 Thakur S, Riyaz B, Patil A, Kaur A, Kapoor B, Mishra V. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomedicine & Pharmacotherapy 2018;106:1011-23. [DOI: 10.1016/j.biopha.2018.07.027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
180 Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:103-109. [PMID: 20134492 DOI: 10.1038/nrgastro.2009.232] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
181 Fukuchi T, Nakase H, Ubukata S, Matsuura M, Yoshino T, Toyonaga T, Shimazu K, Koga H, Yamashita H, Ito D. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease. BMC Gastroenterol. 2013;13:124. [PMID: 25015328 DOI: 10.1186/1471-230x-14-124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
182 Lee H, Schneider Y, Lichtenstein GR. Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis. Dig Dis Sci 2019;64:1138-41. [PMID: 31016561 DOI: 10.1007/s10620-019-05610-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994. [PMID: 17012969 DOI: 10.1097/01.mib.0000231495.92013.5e] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
184 Yassin M, Sadowska Z, Tritsaris K, Kissow H, Hansen CHF, Forman JL, Rogler G, Troelsen JT, Pedersen AE, Olsen J. Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis. J Crohns Colitis 2018;12:1459-74. [PMID: 30137286 DOI: 10.1093/ecco-jcc/jjy112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
185 Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015;47:365-371. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
186 Weiss B, Lebowitz O, Fidder HH, Maza I, Levine A, Shaoul R, Reif S, Bujanover Y, Karban A. Response to Medical Treatment in Patients with Crohn’s Disease: The Role of NOD2/CRAD15, Disease Phenotype, and Age of Diagnosis. Dig Dis Sci 2010;55:1674-80. [DOI: 10.1007/s10620-009-0936-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
187 Latella G, Sferra R, Vetuschi A, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Gaudio E. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest. 2008;38:410-420. [PMID: 18489401 DOI: 10.1111/j.1365-2362.2008.01955.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
188 Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, Dupas JL, Savoye G, Baldé M, Marti R, Lerebours E, Cortot A, Salomez JL, Turck D, Colombel JF. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009;104:2080-8. [PMID: 19436273 DOI: 10.1038/ajg.2009.177] [Cited by in Crossref: 199] [Cited by in F6Publishing: 175] [Article Influence: 15.3] [Reference Citation Analysis]
189 Niess JH, Klaus J, Stephani J, Pflüger C, Degenkolb N, Spaniol U, Mayer B, Lahr G, von Boyen GB. NOD2 polymorphism predicts response to treatment in Crohn’s disease--first steps to a personalized therapy. Dig Dis Sci. 2012;57:879-886. [PMID: 22147245 DOI: 10.1007/s10620-011-1977-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
190 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 615] [Cited by in F6Publishing: 285] [Article Influence: 102.5] [Reference Citation Analysis]
191 Taylor K, Gibson PR. Conventional Therapy of Ulcerative Colitis: Corticosteroids. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 399-412. [DOI: 10.1007/978-3-319-33703-6_39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
192 Coelho MR, Romi MD, Ferreira DMTP, Zaltman C, Soares-Mota M. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. Nutrients. 2020;12. [PMID: 32751776 DOI: 10.3390/nu12082296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
193 Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol. 2007;102:2541-2550. [PMID: 17900329 DOI: 10.1111/j.1572-0241.2007.01537.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 135] [Article Influence: 10.5] [Reference Citation Analysis]
194 Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. J Crohns Colitis. 2013;7:271-279. [PMID: 22883440 DOI: 10.1016/j.crohns.2012.07.010] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
195 Chung SH, Park SU, Cheon JH, Kim ER, Byeon JS, Ye BD, Keum B, Shim KN, Jung SA, Kim JO. Clinical Characteristics and Treatment Outcomes of Cryptogenic Multifocal Ulcerous Stenosing Enteritis in Korea. Dig Dis Sci. 2015;60:2740-2745. [PMID: 25708899 DOI: 10.1007/s10620-015-3595-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
196 Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn‘s disease. Curr Gastroenterol Rep. 2011;13:465-474. [PMID: 21792543 DOI: 10.1007/s11894-011-0220-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
197 Huang LJ, Zhu Q, Lei M, Cao Q. Current use of immunosuppressive agents in inflammatory bowel disease patients in East China. World J Gastroenterol 2009; 15(24): 3055-3059 [PMID: 19554661 DOI: 10.3748/wjg.15.3055] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
198 Cai X, Wang X, He M, Wang Y, Lan M, Zhao Y, Gao F. Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy. Int J Pharm 2021;606:120836. [PMID: 34217824 DOI: 10.1016/j.ijpharm.2021.120836] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis 2005;11:609-12. [PMID: 15905710 DOI: 10.1097/01.mib.0000160743.24772.69] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
200 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120 [PMID: 34168412 DOI: 10.3748/wjg.v27.i22.3109] [Reference Citation Analysis]
201 Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-1352. [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
202 Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, Pereira S, Gonçalves R, Lorenzo A, Carvalho L. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflamm Bowel Dis. 2010;16:1227-1238. [PMID: 19924807 DOI: 10.1002/ibd.21170] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
203 Khan N, Trivedi C, Shah Y, Cole E, Lewis J, Yang Y. The Natural History of Newly Diagnosed Ulcerative Colitis in Patients with Concomitant Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases 2018;24:2062-7. [DOI: 10.1093/ibd/izy106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
204 Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806 [PMID: 16937460 DOI: 10.3748/wjg.v12.i30.4794] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
205 Ishiguro Y, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study. Ther Apher Dial 2021;25:502-12. [PMID: 33029920 DOI: 10.1111/1744-9987.13594] [Reference Citation Analysis]
206 Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis. 2013;7:636-643. [PMID: 23078909 DOI: 10.1016/j.crohns.2012.09.016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
207 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
208 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
209 Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489. e3. [PMID: 21195796 DOI: 10.1016/j.cgh.2010.12.028] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 14.1] [Reference Citation Analysis]
210 Saito YA, Camilleri M. Clinical application of pharmacogenetics in gastrointestinal diseases. Expert Opin Pharmacother 2006;7:1857-69. [PMID: 17020413 DOI: 10.1517/14656566.7.14.1857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
211 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
212 Aceituno M, García-Planella E, Heredia C, Zabana Y, Feu F, Domènech E, Gassull MA, Panés J. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347-52. [PMID: 18050296 DOI: 10.1002/ibd.20322] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
213 Ahrens R, Waddell A, Seidu L, Blanchard C, Carey R, Forbes E, Lampinen M, Wilson T, Cohen E, Stringer K, Ballard E, Munitz A, Xu H, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol. 2008;181:7390-7399. [PMID: 18981162 DOI: 10.4049/jimmunol.181.10.7390] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 7.6] [Reference Citation Analysis]
214 Lopez-sanroman A, Bermejo F, Carrera E, Garcia-plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis: TREATMENT OF STEROID-DEPENDENT COLITIS. Alimentary Pharmacology & Therapeutics 2004;20:161-6. [DOI: 10.1111/j.1365-2036.2004.02030.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
215 Bellizzi A, Barucca V, Fioriti D, Colosimo MT, Mischitelli M, Anzivino E, Chiarini F, Pietropaolo V. Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. J Cell Physiol 2010;224:316-26. [DOI: 10.1002/jcp.22146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
216 Reinisch W, Vogelsang H. Steroid dependency in Crohn's disease. Gastroenterology 2002;123:393-5. [DOI: 10.1053/gast.2002.34592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
217 Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008;27 Suppl 1:15-21. [PMID: 18307645 DOI: 10.1111/j.1365-2036.2008.03606.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
218 Kim CJ, Kovacs-Nolan JA, Yang C, Archbold T, Fan MZ, Mine Y. l-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. J Nutr Biochem. 2010;21:468-475. [PMID: 19428234 DOI: 10.1016/j.jnutbio.2009.01.019] [Cited by in Crossref: 117] [Cited by in F6Publishing: 105] [Article Influence: 9.0] [Reference Citation Analysis]
219 Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn’s disease risk assessment and treatment. Clin Exp Gastroenterol. 2011;4:127-140. [PMID: 21753895 DOI: 10.2147/ceg.s18187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
220 Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM. Therapy of steroid-resistant inflammatory bowel disease. Digestion. 2012;86 Suppl 1:11-15. [PMID: 23051721 DOI: 10.1159/000341952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
221 Fan FY, Sang LX, Jiang M. Catechins and Their Therapeutic Benefits to Inflammatory Bowel Disease. Molecules 2017;22:E484. [PMID: 28335502 DOI: 10.3390/molecules22030484] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 15.6] [Reference Citation Analysis]
222 García-Bosch O, Gisbert JP, Cañas-Ventura A, Merino O, Cabriada JL, García-Sánchez V, Gutiérrez A, Nos P, Peñalva M, Hinojosa J, García-Planella E, Muñoz F, Calvet X, Panés J. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717-22. [PMID: 23142005 DOI: 10.1016/j.crohns.2012.10.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
223 Gestaut MM, Swanson GP. Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease. Rep Pract Oncol Radiother 2017;22:77-82. [PMID: 27920612 DOI: 10.1016/j.rpor.2016.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
224 Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100:1780-1787. [PMID: 16086715 DOI: 10.1111/j.1572-0241.2005.41992.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
225 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol 2013;2013:304894. [PMID: 23691335 DOI: 10.1155/2013/304894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
226 Rai T, Choudhury BN, Kedia S, Bopanna S, Venigalla PM, Garg SK, Singla V, Makharia G, Ahuja V. Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. Dig Dis Sci. 2017;62:1025-1034. [PMID: 28161855 DOI: 10.1007/s10620-017-4450-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
227 Preiss JC, Timmer A, Preiss JC. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd007572] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
228 Thomaz MA, Acedo SC, de Oliveira CC, Pereira JA, Priolli DG, Saad MJ, Pedrazzoli J, Gambero A. Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacological Research 2009;60:341-6. [DOI: 10.1016/j.phrs.2009.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
229 Andrews JM. Le plus ca change: Why we need better biomarkers to predict outcomes in ulcerative colitis: Editorials. Journal of Gastroenterology and Hepatology 2011;26:1085-6. [DOI: 10.1111/j.1440-1746.2011.06754.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
230 Rioux K. What is the prognosis of ulcerative colitis?: . Inflammatory Bowel Diseases 2008;14:S52-3. [DOI: 10.1002/ibd.20574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102:2058-2069. [PMID: 17561966 DOI: 10.1111/j.1572-0241.2007.01343.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 152] [Article Influence: 9.8] [Reference Citation Analysis]
232 Hosain MZ, Yuzuriha K, Khadijah, Takeo M, Kishimura A, Murakami Y, Mori T, Katayama Y. Synergic modulation of the inflammatory state of macrophages utilizing anti-oxidant and phosphatidylserine-containing polymer-lipid hybrid nanoparticles. Medchemcomm 2017;8:1514-20. [PMID: 30108863 DOI: 10.1039/c7md00174f] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
233 Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW; International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156-67. [PMID: 26490195 DOI: 10.1016/S0140-6736(15)00465-1] [Cited by in Crossref: 394] [Cited by in F6Publishing: 191] [Article Influence: 56.3] [Reference Citation Analysis]
234 Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010; 1(5): 87-93 [PMID: 21577301 DOI: 10.4292/wjgpt.v1.i5.87] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
235 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
236 Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn’s disease. Therap Adv Gastroenterol. 2010;3:179-189. [PMID: 21180600 DOI: 10.1177/1756283x09357579] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
237 Domènech E, Vega R, Ojanguren I, Hernández Á, Garcia-planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA. Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy: . Inflammatory Bowel Diseases 2008;14:1373-9. [DOI: 10.1002/ibd.20498] [Cited by in Crossref: 132] [Cited by in F6Publishing: 129] [Article Influence: 9.4] [Reference Citation Analysis]
238 Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9. [PMID: 23714676 DOI: 10.1097/MIB.0b013e3182874065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
239 Kobayashi T, Matsuoka K, Yokoyama Y, Nakamura T, Ino T, Numata T, Shibata H, Aoki H, Matsuno Y, Hibi T. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. J Gastroenterol 2018;53:387-96. [PMID: 28597225 DOI: 10.1007/s00535-017-1356-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
240 Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss JC, Schoepfer AM, Stallmach A, Schmidt C. Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. Journal of Crohn's and Colitis 2012;6:21-8. [DOI: 10.1016/j.crohns.2011.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
241 Fumery M, Pariente B, Sarter H, Charpentier C, Armengol Debeir L, Dupas J, Coevoet H, Peyrin-biroulet L, dʼAgay L, Gower-rousseau C, Savoye G. Natural History of Crohnʼs Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study. Inflammatory Bowel Diseases 2016;22:1698-707. [DOI: 10.1097/mib.0000000000000821] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
242 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
243 Nielsen NK, Wewer V, Skafte L, Paerregaard A. Response pattern recognition in paediatric Crohn's disease patients treated with enteral nutrition. Journal of Crohn's and Colitis 2008;2:233-6. [DOI: 10.1016/j.crohns.2008.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
244 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
245 Hanauer SB. A BALANCING VIEW: Lifetime Channeling of Infliximab for Crohn's Disease. Am J Gastroenterology 2005;100:1438-9. [DOI: 10.1111/j.1572-0241.2005.50622_3.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
246 Suares NC, Hamlin PJ, Greer DP, Warren L, Clark T, Ford AC. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. Aliment Pharmacol Ther 2012;35:284-91. [PMID: 22112005 DOI: 10.1111/j.1365-2036.2011.04925.x] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
247 Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:557-61. [PMID: 30947569 DOI: 10.1080/17474124.2019.1604219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
248 Basson A. Nutrition management in the adult patient with Crohn’s disease. South African Journal of Clinical Nutrition 2016;25:164-72. [DOI: 10.1080/16070658.2012.11734423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
249 Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63:629-642. [PMID: 21857074 DOI: 10.1016/s1734-1140(11)70575-8] [Cited by in Crossref: 135] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
250 Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. The management of refractory Crohn's disease: REVIEW: MANAGEMENT OF REFRACTORY CROHN'S DISEASE. Alimentary Pharmacology & Therapeutics 2002;16:40-7. [DOI: 10.1046/j.1365-2036.16.s4.6.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
251 Ung V, Thanh NX, Wong K, Kroeker KI, Lee T, Wang H, Ohinmaa A, Jacobs P, Fedorak RN. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. Clin Gastroenterol Hepatol 2014;12:1871-8.e8. [PMID: 24674943 DOI: 10.1016/j.cgh.2014.03.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
252 Seegers D, Bouma G, Peña AS. A critical approach to new forms of treatment of Crohn's disease and ulcerative colitis: REVIEW: A CRITICAL APPROACH TO NEW FORMS OF TREATMENT. Alimentary Pharmacology & Therapeutics 2002;16:53-8. [DOI: 10.1046/j.1365-2036.16.s4.8.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
253 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am. 2010;94:1-18. [PMID: 19944795 DOI: 10.1016/j.mcna.2009.08.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
254 Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98:2712-2718. [PMID: 14687822 DOI: 10.1111/j.1572-0241.2003.08674.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 5.4] [Reference Citation Analysis]
255 Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-55. [PMID: 24127239 DOI: 10.1007/s40271-013-0031-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
256 Yu H, MacIsaac D, Wong JJ, Sellers ZM, Wren AA, Bensen R, Kin C, Park KT. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther 2018;47:364-70. [PMID: 29164650 DOI: 10.1111/apt.14430] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 16.8] [Reference Citation Analysis]
257 Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis 2011;5:612-8. [PMID: 22115383 DOI: 10.1016/j.crohns.2011.05.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
258 Aloi M, D’Arcangelo G, Pofi F, Vassallo F, Rizzo V, Nuti F, Di Nardo G, Pierdomenico M, Viola F, Cucchiara S. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis. 2013;7:e509-e515. [PMID: 23583691 DOI: 10.1016/j.crohns.2013.03.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
259 Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573-583. [PMID: 21793126 DOI: 10.1002/ibd.21815] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
260 Loyd KA, Cocayne CG, Cridland JM, Hause WR. Retrospective evaluation of the administration of 25% human albumin to dogs with protein-losing enteropathy: 21 cases (2003-2013). J Vet Emerg Crit Care (San Antonio) 2016;26:587-92. [PMID: 27159733 DOI: 10.1111/vec.12484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
261 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
262 Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS, Sandborn WJ, Faubion WA. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2006;12:1093-1100. [PMID: 17119382 DOI: 10.1097/01.mib.0000235835.32176.85] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
263 Cottone M, Papi C, Orlando A. Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. Expert Rev Gastroenterol Hepatol 2010;4:709-12. [PMID: 21108590 DOI: 10.1586/egh.10.68] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
264 Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol 2010;8:682-687.e1. [PMID: 20363368 DOI: 10.1016/j.cgh.2010.03.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
265 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 487] [Article Influence: 74.7] [Reference Citation Analysis]
266 Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol. 2012;47:359-365. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
267 Yen EF, Kane SV, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008;103:3094-105. [PMID: 18775007 DOI: 10.1111/j.1572-0241.2008.02130.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
268 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
269 Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006;73 Suppl 1:67-76. [PMID: 16498254 DOI: 10.1159/000089781] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
270 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
271 Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55-63. [PMID: 16340635 DOI: 10.1097/01.mcg.0000190762.80615.d4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
272 Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis. 2007;39:617-625. [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
273 Cross RK, Arora M, Finkelstein J. Acceptance of Telemanagement is High in Patients With Inflammatory Bowel Disease: . Journal of Clinical Gastroenterology 2006;40:200-8. [DOI: 10.1097/00004836-200603000-00006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
274 Cullen G, Keegan D, Mulcahy HE, O'donoghue DP. A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease. Clinical Gastroenterology and Hepatology 2009;7:323-8. [DOI: 10.1016/j.cgh.2008.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
275 Tao F, Qian C, Guo W, Luo Q, Xu Q, Sun Y. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin. Biochem Pharmacol 2013;85:798-807. [PMID: 23261528 DOI: 10.1016/j.bcp.2012.12.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
276 Rosh JR. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:302-7. [DOI: 10.1007/s11894-008-0060-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Hanauer SB, Wald A. Acute and chronic megacolon. Curr Treat Options Gastroenterol 2007;10:237-47. [PMID: 17547862 DOI: 10.1007/s11938-007-0017-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
278 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 Asl Baakhtari S, Mccombie A, ten Bokkel Huinink S, Irving P, Siegel CA, Mulder R, Mulder CJ, Gearry R. Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. Dig Dis 2017;36:33-9. [DOI: 10.1159/000478772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
280 Reinisch W, Knobler R, Rutgeerts PJ, Ochsenkühn T, Anderson F, von Tirpitz C, Kaatz M, Janneke van der Woude C, Parenti D, Mannon PJ. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn’s disease: an open-label, multicenter, prospective trial. Inflamm Bowel Dis. 2013;19:293-300. [PMID: 22573600 DOI: 10.1002/ibd.23012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
281 Teshima C, Fedorak RN. Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?: . Inflammatory Bowel Diseases 2008;14:S216-8. [DOI: 10.1002/ibd.20728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
282 Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Reference Citation Analysis]
283 Alharbi OR, Azzam NA, Almalki AS, Almadi MA, Alswat KA, Sadaf N, Aljebreen AM. Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification. World J Gastroenterol 2014; 20(46): 17525-17531 [PMID: 25516667 DOI: 10.3748/wjg.v20.i46.17525] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
284 Li YX, Li SR, Li JX, Yang XY, Wang HH. Efficacy of infliximab in the management of steroid-refractory or steroid-dependent ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2012; 20(21): 1987-1992 [DOI: 10.11569/wcjd.v20.i21.1987] [Reference Citation Analysis]
285 Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51. [PMID: 23639092 DOI: 10.1586/egh.13.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
286 Bellera CL, Di Ianni ME, Talevi A. The application of molecular topology for ulcerative colitis drug discovery. Expert Opin Drug Discov 2018;13:89-101. [PMID: 29088918 DOI: 10.1080/17460441.2018.1396314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
287 Bereshchenko O, Coppo M, Bruscoli S, Biagioli M, Cimino M, Frammartino T, Sorcini D, Venanzi A, Di Sante M, Riccardi C. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. Cell Rep 2014;7:464-75. [PMID: 24703841 DOI: 10.1016/j.celrep.2014.03.004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
288 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 21.9] [Reference Citation Analysis]
289 Carlson TJ, Gonzales-Luna AJ, Wilcox MF, Theriault SG, Alnezary FS, Patel P, Ahn BK, Zasowski EJ, Garey KW. Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use. Open Forum Infect Dis 2021;8:ofab419. [PMID: 34646906 DOI: 10.1093/ofid/ofab419] [Reference Citation Analysis]
290 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
291 Fries W, Costa S, Costantino G, Familiari L. Clinical practice in the management of ulcerative colitis--an Italian survey. Dig Liver Dis 2008;40 Suppl 2:S214-9. [PMID: 18598991 DOI: 10.1016/S1590-8658(08)60528-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
292 Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol. 2008;103:2509-2516. [PMID: 18721243 DOI: 10.1111/j.1572-0241.2008.02103.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
293 Cosnes J, Seksik P. Maladies inflammatoires chroniques de l’intestin : de la sulfasalazine aux biothérapies. Gastroentérologie Clinique et Biologique 2009;33:692-701. [DOI: 10.1016/j.gcb.2009.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
294 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594. [PMID: 19913203 DOI: 10.1016/j.gtc.2009.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
295 Dubinsky MC. Targeting therapy in pediatric inflammatory bowel disease. Curr Treat Options Gastro 2004;7:391-405. [DOI: 10.1007/s11938-004-0052-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
296 Elson CO, Sartor RB, Targan SR, Sandborn WJ. Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis. 2003;9:137-153. [PMID: 12792219 DOI: 10.1097/00054725-200305000-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
297 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
298 Török H, Göke B, Konrad A. Pharmacogenetics of Crohn’s disease. Pharmacogenomics 2008;9:881-93. [DOI: 10.2217/14622416.9.7.881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
299 Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:622-30. [DOI: 10.1097/mib.0000000000000008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]
300 Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García-Sanchez V, Marín-Jiménez I, Rodriguez-Moranta F, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Iborra M, Gutiérrez A, Vera M, Andreu M; Spanish GETECCU group (ENEIDA project). Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis 2014;8:1287-93. [PMID: 24726696 DOI: 10.1016/j.crohns.2014.03.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
301 Miele E, Pascarella F, Quaglietta L, Giannetti E, Greco L, Troncone R, Staiano A. Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis. Aliment Pharmacol Ther 2007;25:933-9. [PMID: 17402997 DOI: 10.1111/j.1365-2036.2007.03291.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
302 Jung C, Colombel JF, Lemann M, Beaugerie L, Allez M, Cosnes J, Vernier-Massouille G, Gornet JM, Gendre JP, Cezard JP. Genotype/phenotype analyses for 53 Crohn’s disease associated genetic polymorphisms. PLoS One. 2012;7:e52223. [PMID: 23300620 DOI: 10.1371/journal.pone.0052223] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
303 Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. World J Gastroenterol 2014; 20(33): 11525-11537 [PMID: 25206259 DOI: 10.3748/wjg.v20.i33.11525] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
304 Sodagari HR, Farzaei MH, Bahramsoltani R, Abdolghaffari AH, Mahmoudi M, Rezaei N. Dietary anthocyanins as a complementary medicinal approach for management of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:807-20. [PMID: 25586636 DOI: 10.1586/17474124.2015.1002086] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
305 Koleva L, Bovt E, Ataullakhanov F, Sinauridze E. Erythrocytes as Carriers: From Drug Delivery to Biosensors. Pharmaceutics 2020;12:E276. [PMID: 32197542 DOI: 10.3390/pharmaceutics12030276] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
306 Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113. [PMID: 18692056 DOI: 10.1053/j.gastro.2008.06.079] [Cited by in Crossref: 390] [Cited by in F6Publishing: 343] [Article Influence: 27.9] [Reference Citation Analysis]
307 Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688. [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
308 Hyams JS. Use of 6-Mercaptopurine/Azathioprine as the Immunomodulator of Choice for Moderately Active Crohnʼs Disease: Pro. Inflammatory Bowel Diseases 2005;11:197-9. [DOI: 10.1097/00054725-200502000-00014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
309 Latella G, Cocco A, Angelucci E, Viscido A, Bacci S, Necozione S, Caprilli R. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen. Dig Liver Dis. 2009;41:269-276. [PMID: 18955023 DOI: 10.1016/j.dld.2008.09.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
310 Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12(23): 3657-3667 [PMID: 16773681 DOI: 10.3748/wjg.v12.i23.3657] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
311 Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, Bressler B, Brown CJ. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 2014;57:83-90. [PMID: 24316950 DOI: 10.1097/DCR.0000000000000003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
312 Brodie JS, Di Marzo V, Guy GW. Polypharmacology Shakes Hands with Complex Aetiopathology. Trends Pharmacol Sci 2015;36:802-21. [PMID: 26434643 DOI: 10.1016/j.tips.2015.08.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
313 Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis. 2010;42:432-435. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
314 Raddatz D, Middel P, Bockemühl M, Benöhr P, Wissmann C, Schwörer H, Ramadori G. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis. Aliment Pharmacol Ther 2004;19:47-61. [PMID: 14687166 DOI: 10.1046/j.1365-2036.2003.01802.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
315 Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterology Clinics of North America 2004;33:303-17. [DOI: 10.1016/j.gtc.2004.02.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
316 Seksik P, Daniel F, Marteau P, Beaugerie L, Cosnes J. [Refractory proctitis]. Gastroenterol Clin Biol 2007;31:393-7. [PMID: 17483776 DOI: 10.1016/s0399-8320(07)89398-5] [Reference Citation Analysis]
317 Biddie SC, Conway-Campbell BL, Lightman SL. Dynamic regulation of glucocorticoid signalling in health and disease. Rheumatology (Oxford) 2012;51:403-12. [PMID: 21891790 DOI: 10.1093/rheumatology/ker215] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
318 Won HS, Park DI, Chon CU, Seok HS, Kim TW, Heo WJ, Lee CK, Eun CS, Han DS, Lee S. Comparison of Infliximab and Infliximab/Azathioprine for Maintenance Therapy in Korean Patients with Luminal Crohn's Disease. Intest Res 2011;9:189. [DOI: 10.5217/ir.2011.9.3.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
319 Yamada S, Yoshino T, Matsuura M, Kimura M, Koshikawa Y, Minami N, Toyonaga T, Honzawa Y, Nakase H. Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res 2015;13:250-8. [PMID: 26131000 DOI: 10.5217/ir.2015.13.3.250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
320 Lasson A, Simrén M, Stotzer P, Isaksson S, Öhman L, Strid H. Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:576-81. [DOI: 10.1097/mib.0b013e31827e78be] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
321 Tao JH, Duan JA, Jiang S, Guo JM, Qian YY, Qian DW. Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from Chrysanthemum morifolium Ramat by gas chromatography with flame ionization detector. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1029-1030:88-94. [PMID: 27428450 DOI: 10.1016/j.jchromb.2016.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
322 Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV Jr, Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis 2014;20:398-415. [PMID: 24280882 DOI: 10.1097/01.MIB.0000435441.30107.8b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
323 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
324 Díez M, Sánchez E, García López S, Teresa Arroyo M, Gomollón F. Tratamiento con infliximab en la colitis ulcerosa: experiencia inicial en dos centros de referencia. Gastroenterología y Hepatología 2007;30:449-53. [DOI: 10.1157/13110489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
325 Umehara Y, Kudo M, Kawasaki M. Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. World J Gastroenterol 2008; 14(34): 5316-5321 [PMID: 18785285 DOI: 10.3748/wjg.14.5316] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
326 Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res 2019;17:36-44. [PMID: 30678445 DOI: 10.5217/ir.2018.00126] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
327 Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS. Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology 2020;158:95-110. [PMID: 31626754 DOI: 10.1053/j.gastro.2019.08.060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
328 Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012; 18(29): 3790-3799 [PMID: 22876029 DOI: 10.3748/wjg.v18.i29.3790] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
329 Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y, Shen Y, Li J, Tan R, Xu Q, Sun Y. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol 2013;85:1504-12. [PMID: 23506741 DOI: 10.1016/j.bcp.2013.03.008] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
330 Wang ZY, Qiu BF. Increased Expression of Matrix Metalloproteinase-1 and 3 in Remission Patients of Steroid-Dependent Ulcerative Colitis. Gastroenterology Res 2010;3:120-4. [PMID: 27942289 DOI: 10.4021/gr2010.05.208w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
331 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
332 Fokam Tagne MA, Tchoffo A, Noubissi PA, Mazo AG, Kom B, Ngakou Mukam J, Sokeng Dongmo S, Kamgang R. Effects of hydro-ethanolic extract of leaves of Maesa lanceolata (Mursinaceae) on acetic acid-induced ulcerative colitis in rats. Inflammopharmacology 2021;29:1211-23. [PMID: 34101116 DOI: 10.1007/s10787-021-00825-8] [Reference Citation Analysis]
333 Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma BK. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet Genomics. 2009;19:77-85. [PMID: 19005421 DOI: 10.1097/fpc.0b013e32831a9abe] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
334 Peyrin-biroulet L, Billioud V, D'haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PDR, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel J, Travis S, Sandborn WJ. Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. American Journal of Gastroenterology 2012;107:1770-6. [DOI: 10.1038/ajg.2012.117] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 6.9] [Reference Citation Analysis]
335 Chebli JMF, Gaburri PD, De Souza AFM, Pinto ALT, Chebli LA, Felga GEG, Forn CG, Pimentel CFMG. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: Open-label prospective study. J Gastroenterol Hepatol 2007;22:268-74. [DOI: 10.1111/j.1440-1746.2006.04393.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
336 Fukuchi T, Koga H, Kaichi S, Ishikawa A, Horita T, Araki R, Yokota A, Namba Y, Kyo M, Eguchi T, Shimazu K. Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis Is Suitable for Elderly Patients With Active Ulcerative Colitis Taking no Corticosteroids or Biologics. Ther Apher Dial. 2019;23:224-232. [PMID: 31025824 DOI: 10.1111/1744-9987.12819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P. Infliximab dependency in children with Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009;29:792-9. [DOI: 10.1111/j.1365-2036.2009.03926.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
338 Mwinyi J, Wenger C, Eloranta JJ, Kullak-Ublick GA. Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients. World J Gastroenterol 2010; 16(31): 3888-3896 [PMID: 20712049 DOI: 10.3748/wjg.v16.i31.3888] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
339 Targownik LE, Bernstein CN, Benchimol EI, Kaplan GG, Singh H, Tennakoon A, Nugent Z, Coward SB, Kuenzig ME, Murthy SK. Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. Am J Gastroenterol 2021;116:1284-93. [PMID: 33767103 DOI: 10.14309/ajg.0000000000001220] [Reference Citation Analysis]
340 Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111-122. [PMID: 17229236 DOI: 10.1111/j.1365-2036.2006.03156.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
341 Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012;143:356-364.e1. [PMID: 22549092 DOI: 10.1053/j.gastro.2012.04.043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
342 Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126-137. [PMID: 19392869 DOI: 10.1111/j.1365-2036.2009.04023.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 10.7] [Reference Citation Analysis]
343 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297. [PMID: 19861953 DOI: 10.1038/ajg.2009.579] [Cited by in Crossref: 566] [Cited by in F6Publishing: 508] [Article Influence: 43.5] [Reference Citation Analysis]
344 Bultman E, Kuipers EJ, Van Der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease: Systematic review: steroid withdrawal during anti-TNF treatment. Alimentary Pharmacology & Therapeutics 2010;32:313-23. [DOI: 10.1111/j.1365-2036.2010.04373.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
345 Jakobsen C, Bartek J, Wewer V, Vind I, Munkholm P, Groen R, Paerregaard A. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease - a population-based study: Differences between paediatric and adult IBD. Alimentary Pharmacology & Therapeutics 2011;34:1217-24. [DOI: 10.1111/j.1365-2036.2011.04857.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 8.3] [Reference Citation Analysis]
346 Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72. [PMID: 15735477 DOI: 10.1097/01.mpg.0000154660.62359.fe] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
347 Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV Jr; Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001-2010. [PMID: 23624887 DOI: 10.1097/mib.0b013e318281f3bb] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
348 van der Woude CJ, Hommes DW. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Review of Gastroenterology & Hepatology 2014;1:243-8. [DOI: 10.1586/17474124.1.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
349 Icht O, Yanai H, Ron Y, Rosner G, Yaron A, Waizbard A, Ziv-Baran T, Fishman S, Dotan I. Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies. Digestion 2017;96:135-41. [PMID: 28848118 DOI: 10.1159/000477438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
350 Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLoS One. 2017;12:e0169845. [PMID: 28076386 DOI: 10.1371/journal.pone.0169845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
351 Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009; 15(13): 1594-1599 [PMID: 19340901 DOI: 10.3748/wjg.15.1594] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
352 Park Y, Cheon JH, Park YL, Ye BD, Kim YS, Han DS, Kim JS, Hong SN, Kim YH, Jeon SR, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases (KASID). Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study. Inflamm Bowel Dis. 2017;23:1071-1079. [PMID: 28410345 DOI: 10.1097/mib.0000000000001106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
353 Wang Y, Tang Q, Duan P, Yang L. Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. Immunopharmacol Immunotoxicol 2018;40:476-82. [PMID: 30111198 DOI: 10.1080/08923973.2018.1469145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
354 Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
355 Sands BE. The risks and benefits of early immunosuppression and biological therapy. Dig Dis. 2012;30 Suppl 3:100-106. [PMID: 23295699 DOI: 10.1159/000342731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
356 Reuter KC, Grunwitz CR, Kaminski BM, Steinhilber D, Radeke HH, Stein J. Selective Glucocorticoid Receptor Agonists for the Treatment of Inflammatory Bowel Disease: Studies in Mice with Acute Trinitrobenzene Sulfonic Acid Colitis. J Pharmacol Exp Ther 2012;341:68-80. [DOI: 10.1124/jpet.111.183947] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
357 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
358 Simon M. Rectocolite hémorragique: traitement médical. Colon Rectum 2013;7:11-7. [DOI: 10.1007/s11725-013-0434-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
359 Tamboli CP. Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 2007;87:697-725. [DOI: 10.1016/j.suc.2007.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
360 Beniwal-Patel P, Saha S. The role of integrin antagonists in the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:1815-23. [PMID: 25288228 DOI: 10.1517/14712598.2014.967209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
361 Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther. 2015;41:87-98. [PMID: 25382737 DOI: 10.1111/apt.13017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
362 Li J, Wang F, Zhang HJ, Sheng JQ, Yan WF, Ma MX, Fan RY, Gu F, Li CF, Chen DF, Zheng P, Gu YP, Cao Q, Yang H, Qian JM, Hu PJ, Xia B. Corticosteroid therapy in ulcerative colitis: Clinical response and predictors. World J Gastroenterol 2015; 21(10): 3005-3015 [PMID: 25780299 DOI: 10.3748/wjg.v21.i10.3005] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
363 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 311] [Article Influence: 97.5] [Reference Citation Analysis]
364 Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, Cho YK, Yu CS, Choi KS, Chung JW. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278-283. [PMID: 17206722 DOI: 10.1002/ibd.20015] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 5.9] [Reference Citation Analysis]
365 Triadafilopoulos G. Glucocorticoid therapy for gastrointestinal diseases. Expert Opinion on Drug Safety 2014;13:563-72. [DOI: 10.1517/14740338.2014.904852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
366 Patil SA, Rustgi A, Quezada SM, Flasar MH, Vandermeer F, Cross RK. Anti-TNF Therapy Is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2013;19:92-8. [DOI: 10.1002/ibd.22982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
367 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
368 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
369 Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn’s Disease. Drugs 2014;74:313-24. [DOI: 10.1007/s40265-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
370 Eronen H, Ilus T, Jussila A, Huhtala H, Collin P, Oksanen P. Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids. Scand J Gastroenterol 2021;56:234-8. [PMID: 33496198 DOI: 10.1080/00365521.2020.1867892] [Reference Citation Analysis]
371 Garcia-Planella E, Mañosa M, Van Domselaar M, Gordillo J, Zabana Y, Cabré E, López San Román A, Domènech E. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis 2012;44:206-10. [PMID: 22079262 DOI: 10.1016/j.dld.2011.10.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
372 Vermeire S, Van Assche G, Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 2010; 16(21): 2609-2615 [PMID: 20518082 DOI: 10.3748/wjg.v16.i21.2609] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
373 Feagan BG. Medical Management of Ulcerative Colitis in 2006: What's on the Horizon? Am J Gastroenterology 2007;102:S7-S13. [DOI: 10.1111/j.1572-0241.2007.01292.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
374 Mañosa M, Cabré E, Garcia-planella E, Bernal I, Gordillo J, Esteve M, Zabana Y, Gassull MA, Domènech E. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids: . Inflammatory Bowel Diseases 2011;17:2497-502. [DOI: 10.1002/ibd.21634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
375 Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, Im JP, Park SJ, Kim YS, Kim TO. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol. 2013;28:1829-1833. [PMID: 23829336 DOI: 10.1111/jgh.12324] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
376 Ponsky T, Hindle A, Sandler A. Inflammatory bowel disease in the pediatric patient. Surg Clin North Am. 2007;87:643-658. [PMID: 17560417 DOI: 10.1016/j.suc.2007.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
377 Smith MA, Marinaki AM, Sanderson JD. Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics. 2010;11:421-437. [PMID: 20235796 DOI: 10.2217/pgs.10.4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
378 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
379 Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis. 2013;7:e692-e697. [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
380 Matsumoto S, Kawamura H, Nishikawa T, Sagihara N, Miyatani H, Mashima H. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol 2017;10:249-58. [PMID: 29026326 DOI: 10.2147/CEG.S143224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
381 Lorén V, Cabré E, Ojanguren I, Domènech E, Pedrosa E, García-Jaraquemada A, Mañosa M, Manyé J. Interleukin-10 Enhances the Intestinal Epithelial Barrier in the Presence of Corticosteroids through p38 MAPK Activity in Caco-2 Monolayers: A Possible Mechanism for Steroid Responsiveness in Ulcerative Colitis. PLoS One 2015;10:e0130921. [PMID: 26090671 DOI: 10.1371/journal.pone.0130921] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
382 Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
383 Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12-18. [PMID: 17206634 DOI: 10.1002/ibd.20049] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
384 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 178] [Article Influence: 10.5] [Reference Citation Analysis]
385 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
386 Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17:7-19. [PMID: 20011280 DOI: 10.1055/s-2004-823066] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
387 Terao S, Yamashiro K, Tamura I, Hirano T, Ohkusa T, Kato K. Antibiotic Combination Therapy for Steroid Withdrawal in Steroid-Dependent Ulcerative Colitis. Digestion 2011;83:198-203. [DOI: 10.1159/000321811] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
388 Leung Y, Panaccione R. Anti-adhesion molecule strategies for Crohn disease. BioDrugs 2008;22:259-64. [PMID: 18611068 DOI: 10.2165/00063030-200822040-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
389 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
390 Desmond AN, Shanahan F. Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Ir J Med Sci. 2012;181:65-71. [PMID: 21947686 DOI: 10.1007/s11845-011-0760-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
391 D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010;4:153-60. [PMID: 21122499 DOI: 10.1016/j.crohns.2009.09.007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
392 Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, de’Angelis GL, Federici T. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis. 2008;40 Suppl 2:S260-S264. [PMID: 18598998 DOI: 10.1016/s1590-8658(08)60535-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
393 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Reference Citation Analysis]
394 Ocón B, Aranda CJ, Gámez-Belmonte R, Suárez MD, Zarzuelo A, Martínez-Augustin O, Sánchez de Medina F. The glucocorticoid budesonide has protective and deleterious effects in experimental colitis in mice. Biochem Pharmacol 2016;116:73-88. [PMID: 27431777 DOI: 10.1016/j.bcp.2016.07.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
395 Bantel H, Schmitz ML, Raible A, Gregor M, Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J. 2002;16:1832-1834. [PMID: 12223450 DOI: 10.1096/fj.02-0223fje] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 3.6] [Reference Citation Analysis]
396 Velayos F, Mahadevan U. Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery? Clin Gastroenterol Hepatol 2007;5:668-71. [PMID: 17544992 DOI: 10.1016/j.cgh.2007.03.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
397 López San Román A, Rivero Fernández M. Estado actual del tratamiento de la enfermedad inflamatoria intestinal. Revista Clínica Española 2007;207:298-300. [DOI: 10.1157/13106853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
398 Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
399 Guo W, Hu S, Elgehama A, Shao F, Ren R, Liu W, Zhang W, Wang X, Tan R, Xu Q, Sun Y, Jiao R. Fumigaclavine C ameliorates dextran sulfate sodium-induced murine experimental colitis via NLRP3 inflammasome inhibition. J Pharmacol Sci 2015;129:101-6. [PMID: 26320672 DOI: 10.1016/j.jphs.2015.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
400 Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2011;7:419-428. [PMID: 21790284 DOI: 10.1586/eci.11.34] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
401 Zannolli R, Buoni S, Betti G, Salvucci S, Plebani A, Soresina A, Pietrogrande MC, Martino S, Leuzzi V, Finocchi A, Micheli R, Rossi LN, Brusco A, Misiani F, Fois A, Hayek J, Kelly C, Chessa L. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 2012;27:1312-6. [PMID: 22927201 DOI: 10.1002/mds.25126] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
402 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85. [PMID: 20134489 DOI: 10.1038/nrgastro.2009.220] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
403 Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600. [PMID: 24502344 DOI: 10.1517/14712598.2014.885945] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
404 Ho G, Lees C, Satsangi J. Ulcerative colitis. Medicine 2007;35:277-82. [DOI: 10.1016/j.mpmed.2007.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
405 Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003;171:5514-5520. [PMID: 14607958 DOI: 10.4049/jimmunol.171.10.5514] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
406 Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, Xu H, Xiang J, He Z, Zhang T, Nie Y, Wu K, Fan D, Ji G, Zhang F. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med. 2015;13:298. [PMID: 26363929 DOI: 10.1186/s12967-015-0646-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
407 Pontes C, Vives R, Torres F, Panés J. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflamm Bowel Dis 2014;20:2004-12. [PMID: 25192498 DOI: 10.1097/MIB.0000000000000166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
408 Peyrin-biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics 2011;33:870-9. [DOI: 10.1111/j.1365-2036.2011.04599.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 9.5] [Reference Citation Analysis]
409 Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
410 Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold Ø, Aadland E, Vatn M, Moum B. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol. 2005;17:1037-1045. [PMID: 16148548 DOI: 10.1097/00042737-200510000-00006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
411 Ananthakrishnan AN, Xavier RJ. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis 2013;19:2021-30. [PMID: 23644824 DOI: 10.1097/MIB.0b013e318281f5c5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
412 Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3. [PMID: 24512909 DOI: 10.1053/j.gastro.2013.10.052] [Cited by in Crossref: 512] [Cited by in F6Publishing: 445] [Article Influence: 64.0] [Reference Citation Analysis]
413 Olivera P, Danese S, Peyrin-biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 12.0] [Reference Citation Analysis]
414 Farombi E, Adedara I, Ajayi B, Idowu T, Eriomala O, Akinbote F. 6-Gingerol improves testicular function in mice model of chronic ulcerative colitis. Hum Exp Toxicol 2017;37:358-72. [DOI: 10.1177/0960327117703689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
415 Castro M, Knafelz D, Rossi L, Ambrosini MI, Papadatou B, Mambrini G, Magnani M. Periodic Treatment with Autologous Erythrocytes Loaded with Dexamethasone 21-Phosphate for Fistulizing Pediatric Crohn's Disease: Case Report. Journal of Pediatric Gastroenterology & Nutrition 2006;42:313-5. [DOI: 10.1097/01.mpg.0000188006.59128.47] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
416 Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol 2006; 12(20): 3204-3212 [PMID: 16718840 DOI: 10.3748/wjg.v12.i20.3204] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
417 Fumery M, Pariente B, Sarter H, Savoye G, Spyckerelle C, Djeddi D, Mouterde O, Bouguen G, Ley D, Peneau A, Dupas J, Turck D, Gower-rousseau C. Long-term outcome of pediatric-onset Crohn’s disease: A population-based cohort study. Digestive and Liver Disease 2019;51:496-502. [DOI: 10.1016/j.dld.2018.11.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
418 Liu C, Ji S, Ding Y, Zhou L, Liu X, Li W. Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis. Ir J Med Sci 2018;187:935-42. [DOI: 10.1007/s11845-018-1752-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
419 Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 2002;4:497-505. [DOI: 10.1007/s11894-002-0026-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
420 Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion 2005;71:19-25. [PMID: 15711044 DOI: 10.1159/000083867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
421 Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top-down or step-up? Dig Dis. 2007;25:260-266. [PMID: 17827952 DOI: 10.1159/000103897] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
422 Xuan M, Li H, Fu R, Yang Y, Zhang D, Zhang X, Yang R. Lack of association between NR3C1 polymorphism and glucocorticoid resistance in Chinese patients with immune thrombocytopenia. Platelets 2014;25:125-8. [PMID: 23527567 DOI: 10.3109/09537104.2013.779369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
423 Chen G, Cao S, Liu F, Liu Y. miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. Biochem J 2015;471:357-67. [PMID: 26303523 DOI: 10.1042/BJ20150095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
424 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
425 Rieder F, Latella G, Magro F, Yuksel ES, Higgins PDR, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d’Hoore A, Pellino G, Dignass AU. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. ECCOJC 2016;10:873-85. [DOI: 10.1093/ecco-jcc/jjw055] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 17.0] [Reference Citation Analysis]
426 Murphy SJ, Kornbluth A. Serologic and genetic markers do not aid in the determination of the clinical course and severity of patients with inflammatory bowel disease: . Inflammatory Bowel Diseases 2008;14:129-31. [DOI: 10.1002/ibd.20291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
427 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
428 Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963-2969. [PMID: 23812861 DOI: 10.1007/s10620-013-2748-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
429 Barreiro-Alonso E, Saro-Gismera C, Sánchez M. Outcomes and prediction of corticosteroid therapy after successive courses of ulcerative colitis treatments. Expert Rev Gastroenterol Hepatol 2018;12:733-41. [PMID: 29911903 DOI: 10.1080/17474124.2018.1489231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
430 Figueroa JJ, Loftus EV Jr, Harmsen WS, Dyck PJ, Klein CJ. Peripheral neuropathy incidence in inflammatory bowel disease: a population-based study. Neurology 2013;80:1693-7. [PMID: 23576624 DOI: 10.1212/WNL.0b013e3182904d16] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
431 Yanagisawa K, Murakami M, Kondo Y, Oguma S, Kobayashi S, Miyasaka H, Shinohara T, Tomori A, Nakano Y, Furuhata S, Ikezoe M. Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients With Ulcerative Colitis. Ther Apher Dial 2019;23:217-23. [PMID: 31025815 DOI: 10.1111/1744-9987.12818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
432 Viazis N, Giakoumis M, Bamias G, Goukos D, Koukouratos T, Katopodi K, Karatzas P, Triantos C, Tsolias C, Theocharis G, Daikos GL, Ladas SD, Karamanolis DG, Mantzaris GJ. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Dig Liver Dis 2017;49:29-33. [PMID: 27866814 DOI: 10.1016/j.dld.2016.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
433 Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92. [DOI: 10.1053/j.gastro.2004.02.071] [Cited by in Crossref: 120] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
434 Siegel CA. What options do we have for induction therapy for Crohn's disease? Dig Dis 2010;28:543-7. [PMID: 20926884 DOI: 10.1159/000320414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
435 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
436 Strauch U, Schölmerich J. Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs 2010;15:309-22. [PMID: 20402560 DOI: 10.1517/14728214.2010.480972] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Casili G, Cordaro M, Impellizzeri D, Bruschetta G, Paterniti I, Cuzzocrea S, Esposito E. Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis. J Crohns Colitis 2016;10:472-83. [PMID: 26690241 DOI: 10.1093/ecco-jcc/jjv231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
438 Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16:343-356.e3. [PMID: 28625817 DOI: 10.1016/j.cgh.2017.06.016] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 23.2] [Reference Citation Analysis]
439 Bello C, Belaiche J, Louis E, Reenaers C. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196-202. [PMID: 21575881 DOI: 10.1016/j.crohns.2010.12.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
440 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
441 Sood A, Ahuja V, Midha V, Sinha SK, Pai CG, Kedia S, Mehta V, Bopanna S, Abraham P, Banerjee R, Bhatia S, Chakravartty K, Dadhich S, Desai D, Dwivedi M, Goswami B, Kaur K, Khosla R, Kumar A, Mahajan R, Misra SP, Peddi K, Singh SP, Singh A. Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res 2020;18:355-78. [PMID: 32646198 DOI: 10.5217/ir.2019.09176] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
442 Christophi GP, Rengarajan A, Ciorba MA. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol 2016;9:125-30. [PMID: 27274301 DOI: 10.2147/CEG.S80237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
443 Sands BE, Siegel CA. Crohn's Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 1941-1973.e9. [DOI: 10.1016/b978-1-4160-6189-2.00111-6] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
444 Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Dig Dis Sci 2019;64:1612-21. [PMID: 30604371 DOI: 10.1007/s10620-018-5429-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
445 Michelassi F, Sultan S. Surgical treatment of complex small bowel Crohn disease. Ann Surg. 2014;260:230-235. [PMID: 24743631 DOI: 10.1097/SLA.0000000000000697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
446 Asano K, Esaki M, Umeno J, Hirano A, Maehata Y, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis. J Gastroenterol 2015;50:1094-102. [PMID: 25787843 DOI: 10.1007/s00535-015-1062-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
447 Alós R, Hinojosa J. Timing of surgery in Crohn’s disease: A key issue in the management. World J Gastroenterol 2008; 14(36): 5532-5539 [PMID: 18810772 DOI: 10.3748/wjg.14.5532] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
448 Bjerrum JT, Rantalainen M, Wang Y, Olsen J, Nielsen OH. Integration of transcriptomics and metabonomics: improving diagnostics, biomarker identification and phenotyping in ulcerative colitis. Metabolomics. 2014;10:280-290. [PMID: 25221466 DOI: 10.1007/s11306-013-0580-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
449 Mañosa M, García V, Castro L, García-Bosch O, Chaparro M, Barreiro-de Acosta M, Carpio D, Aguas M. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. J Crohns Colitis 2011;5:397-401. [PMID: 21939912 DOI: 10.1016/j.crohns.2011.03.012] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
450 Foster EN, Quiros JA, Prindiville TP. Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease. J Clin Gastroenterol 2008;42:880-5. [PMID: 18645528 DOI: 10.1097/MCG.0b013e3181354440] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
451 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 516] [Article Influence: 46.6] [Reference Citation Analysis]
452 Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017; 8(2): 114-119 [PMID: 28533920 DOI: 10.4292/wjgpt.v8.i2.114] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
453 Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005;21:373-84. [PMID: 15709987 DOI: 10.1111/j.1365-2036.2005.02336.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
454 Schölmerich J. Systemic and topical steroids in inflammatory bowel disease: REVIEW: STEROID TREATMENT IN INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2004;20:66-74. [DOI: 10.1111/j.1365-2036.2004.02059.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
455 Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet. 2002;359:331-340. [PMID: 11830216 DOI: 10.1016/s0140-6736(02)07499-8] [Cited by in Crossref: 201] [Cited by in F6Publishing: 65] [Article Influence: 10.1] [Reference Citation Analysis]
456 Florholmen J, Øverland G, Olsen T, Rismo R, Cui G, Christiansen I, Paulssen EJ, Goll R. Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis. Ulcers 2011;2011:1-7. [DOI: 10.1155/2011/156407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
457 Shimazu K, Fukuchi T, Kim I, Noguchi Y, Iwata M, Koyama S, Ubukata S, Tanaka A. Efficacy and Usefulness of New Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis in Active Ulcerative Colitis Patients Without Corticosteroids and Biologics. Ther Apher Dial. 2016;20:383-389. [PMID: 27523079 DOI: 10.1111/1744-9987.12470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
458 Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688. [PMID: 12198692 DOI: 10.1053/gast.2002.35393] [Cited by in Crossref: 337] [Cited by in F6Publishing: 313] [Article Influence: 16.9] [Reference Citation Analysis]
459 Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease--evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 36] [Article Influence: 0.7] [Reference Citation Analysis]
460 Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents. Nat Rev Gastroenterol Hepatol 2005;2:572-9. [DOI: 10.1038/ncpgasthep0338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
461 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
462 Allenspach K, Bergman P, Sauter S, Gröne A, Doherr M, Gaschen F. P-glycoprotein Expression in Lamina Propria Lymphocytes of Duodenal Biopsy Samples in Dogs with Chronic Idiopathic Enteropathies. Journal of Comparative Pathology 2006;134:1-7. [DOI: 10.1016/j.jcpa.2005.06.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
463 Okabayashi S, Kobayashi T, Hibi T. Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? J Anus Rectum Colon 2020;4:1-13. [PMID: 32002471 DOI: 10.23922/jarc.2019-003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
464 Speca S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012; 18(28): 3635-3661 [PMID: 22851857 DOI: 10.3748/wjg.v18.i28.3635] [Cited by in CrossRef: 140] [Cited by in F6Publishing: 125] [Article Influence: 14.0] [Reference Citation Analysis]
465 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
466 Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008;28:1214-1220. [PMID: 18761706 DOI: 10.1111/j.1365-2036.2008.03841.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
467 Volk N, Siegel CA. Defining Failure of Medical Therapy for Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:74-7. [PMID: 30016434 DOI: 10.1093/ibd/izy238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
468 Ho G, Lees C, Satsangi J. Ulcerative colitis. Medicine 2011;39:224-8. [DOI: 10.1016/j.mpmed.2011.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
469 McSharry K, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther. 2011;34:1282-1294. [PMID: 21999607 DOI: 10.1111/j.1365-2036.2011.04873.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
470 Llaó J, Naves JE, Ruiz-cerulla A, Marín L, Mañosa M, Rodríguez-alonso L, Cabré E, Garcia-planella E, Guardiola J, Domènech E. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. Journal of Crohn's and Colitis 2014;8:1523-8. [DOI: 10.1016/j.crohns.2014.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
471 Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S. Efficacy of adalimumab in moderate-to-severe pediatric Crohn’s disease. Am J Gastroenterol. 2009;104:2566-2571. [PMID: 19550415 DOI: 10.1038/ajg.2009.372] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
472 Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol 2017; 23(36): 6628-6638 [PMID: 29085208 DOI: 10.3748/wjg.v23.i36.6628] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 10.6] [Reference Citation Analysis]
473 Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512-530. [PMID: 11832465 DOI: 10.1053/gast.2002.31072] [Cited by in Crossref: 451] [Cited by in F6Publishing: 411] [Article Influence: 22.6] [Reference Citation Analysis]
474 Panaccione R. Crohn's disease: we are in it for the long haul. Interview by Paul C Adams. Can J Gastroenterol 2008;22:803-4. [PMID: 19006852 DOI: 10.1155/2008/836576] [Reference Citation Analysis]
475 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
476 Li C, Kuemmerle JF. Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:1250-1258. [PMID: 24831560 DOI: 10.1097/mib.0000000000000043] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 9.4] [Reference Citation Analysis]
477 Absah I, Stephens M. Adjunctive treatment to antitumor necrosis factor in pediatric patient with refractory Crohn’s disease. Curr Opin Pediatr. 2013;Epub ahead of print. [PMID: 23995433 DOI: 10.1097/mop.0b013e328364df22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
478 Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, Vasseur F, Dupas JL, Cortot A, Dauchet L, Peyrin-Biroulet L, Lerebours E, Colombel JF, Gower-Rousseau C. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423-432. [PMID: 23408350 DOI: 10.1136/gutjnl-2012-303864] [Cited by in Crossref: 188] [Cited by in F6Publishing: 167] [Article Influence: 20.9] [Reference Citation Analysis]
479 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
480 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
481 Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006;55:437-41. [PMID: 16531519 DOI: 10.1136/gut.2005.078055] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
482 Naganuma M, Hirai F, Kobayashi K, Watanabe K, Takeuchi K, Aoyama N, Nozawa H, Motoya S, Ohmori T, Harada A, Nagai Y, Abe T, Yamada Y, Inagaki K, Shimizu N, Kanai T, Watanabe M; ESCORT study Group. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. PLoS One 2019;14:e0220413. [PMID: 31381615 DOI: 10.1371/journal.pone.0220413] [Reference Citation Analysis]
483 Waljee AK, Wiitala WL, Govani S, Stidham R, Saini S, Hou J, Feagins LA, Khan N, Good CB, Vijan S, Higgins PD. Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. PLoS One. 2016;11:e0158017. [PMID: 27336296 DOI: 10.1371/journal.pone.0158017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 10.7] [Reference Citation Analysis]
484 Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009;54:269-278. [PMID: 19934608 DOI: 10.4166/kjg.2009.54.2.108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
485 Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers J, Pittet V, Vader J, Froehlich F, Felley C. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel—EPACT II. Journal of Crohn's and Colitis 2009;3:232-40. [DOI: 10.1016/j.crohns.2009.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
486 Jakobsen C, Munkholm P, Paerregaard A, Wewer V. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators—A population-based study: . Inflammatory Bowel Diseases 2011;17:1731-40. [DOI: 10.1002/ibd.21559] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
487 Lightner AL, Cima R. Use of the Rochester Epidemiology Project for Clinical Research in Colon and Rectal Surgery. Clin Colon Rectal Surg 2019;32:8-15. [PMID: 30647541 DOI: 10.1055/s-0038-1673349] [Reference Citation Analysis]
488 Shastri S, Shinde T, Sohal SS, Gueven N, Eri R. Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms. Int J Mol Sci 2020;21:E484. [PMID: 31940911 DOI: 10.3390/ijms21020484] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
489 Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197. [PMID: 19249397 DOI: 10.1053/j.gastro.2009.02.001] [Cited by in Crossref: 267] [Cited by in F6Publishing: 252] [Article Influence: 20.5] [Reference Citation Analysis]
490 Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:1440-52. [PMID: 29601644 DOI: 10.1111/apt.14631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
491 Kim J, Kim HJ, Lee CK, Kim H, Shin AR, Kang KH, Kim MK, Park HJ, Chung HH, Hwang EJ. Predictors of Steroid Treatment Failure and Validation of Previous Models for Severe Attacks of Ulcerative Colitis. Intest Res 2012;10:251. [DOI: 10.5217/ir.2012.10.3.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
492 Zrieki A, Farinotti R, Buyse M. Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. Eur J Pharmacol 2010;636:189-97. [PMID: 20361960 DOI: 10.1016/j.ejphar.2010.03.039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
493 Buchman AL, Paine MF, Wallin A, Ludington SS. A Higher Dose Requirement of Tacrolimus in Active Crohn's Disease May Be Related to a High Intestinal P-Glycoprotein Content. Dig Dis Sci 2005;50:2312-5. [DOI: 10.1007/s10620-005-3053-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
494 Scott FI, Lichtenstein GR. Approach to the Patient with Mild Crohn’s Disease: a 2016 Update. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-016-0523-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
495 Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease 2008;40:S271-9. [DOI: 10.1016/s1590-8658(08)60537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
496 Markowitz J, Markowitz JE, Bousvaros A, Crandall W, Faubion W, Kirschner BS, Perrault J, Rosh J, Winter H. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:145-51. [PMID: 16056092 DOI: 10.1097/01.mpg.0000172746.86973.ef] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
497 González-lama Y, López-san Román A, Marín-jiménez I, Casis B, Vera I, Bermejo F, Lázaro Pérez-calle J, Taxonera C, Martínez-silva F, Menchén L, Martínez-montiel P, Calvo M, Antonio Carneros J, López P, Luis Mendoza J, María Milicua J, Huerta A, Sánchez F, Abreu L, López-palacios N, Maté J, Gisberta JP. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterología y Hepatología 2008;31:421-6. [DOI: 10.1157/13125587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
498 Bálint A, Farkas K, Szepes Z, Nagy F, Szűcs M, Tiszlavicz L, Bor R, Milassin Á, Rutka M, Fábián A, Molnár T. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system. BMC Gastroenterol 2018;18:7. [PMID: 29310593 DOI: 10.1186/s12876-017-0725-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
499 Xiong Y, Wang GZ, Zhou JQ, Xia BQ, Wang XY, Jiang B. Serum antibodies to microbial antigens for Crohn’s disease progression: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:733-742. [PMID: 24901819 DOI: 10.1097/meg.0000000000000102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
500 Gómez-Gómez GJ, Masedo &, Yela C, Martínez-Montiel MDP, Casís B. Current stage in inflammatory bowel disease: What is next? World J Gastroenterol 2015; 21(40): 11282-11303 [PMID: 26525013 DOI: 10.3748/wjg.v21.i40.11282] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
501 Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432-52. [PMID: 32920854 DOI: 10.1111/apt.15998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
502 Park SK, Yang SK, Ye BD, Kim KJ, Yang DH, Jung KW, Park SH, Kim JW, Byeon JS, Myung SJ, Kim JH. The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis. Scand J Gastroenterol. 2013;48:1386-1393. [PMID: 24164382 DOI: 10.3109/00365521.2013.845908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
503 Yokoyama Y, Watanabe K, Ito H, Nishishita M, Sawada K, Okuyama Y, Okazaki K, Fujii H, Nakase H, Masuda T, Fukunaga K, Andoh A, Nakamura S. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy. 2015;17:680-688. [PMID: 25804800 DOI: 10.1016/j.jcyt.2015.02.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
504 Teshima C, Fedorak RN. Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?: . Inflammatory Bowel Diseases 2008;14:S216-8. [DOI: 10.1097/00054725-200810001-00102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
505 Khanna R, Preiss JC, MacDonald JK, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2015;:CD007572. [PMID: 25942580 DOI: 10.1002/14651858.CD007572.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
506 Miyata M, Kasugai K, Ishikawa T, Kakumu S, Onishi M, Mori T. Rebamipide Enemas–New Effective Treatment for Patients with Corticosteroid Dependent or Resistant Ulcerative Colitis. Dig Dis Sci 2005;50:S119-23. [DOI: 10.1007/s10620-005-2816-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
507 Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study. Gastroenterol Res Pract 2016;2016:5956316. [PMID: 27413367 DOI: 10.1155/2016/5956316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
508 Cross RK, Jung C, Wasan S, Joshi G, Sawyer R, Roghmann MC. Racial differences in disease phenotypes in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:192-198. [PMID: 16534420 DOI: 10.1097/01.mib.0000217767.98389.20] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
509 Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008;28:606-613. [PMID: 18564323 DOI: 10.1111/j.1365-2036.2008.03772.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
510 Cury DB, Moss AC, Elias G, Nakao A. Adalimumab for cutaneous metastatic Crohn's disease. Inflamm Bowel Dis 2010;16:723-4. [PMID: 19728388 DOI: 10.1002/ibd.21082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
511 D'Ovidio V, Meo D, Viscido A, Bresci G, Vernia P, Caprilli R. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol 2011; 17(14): 1831-1835 [PMID: 21528055 DOI: 10.3748/wjg.v17.i14.1831] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
512 Yoshizaki A, Nakayama T, Naito S, Sekine I. Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis. Dig Dis Sci. 2009;54:2094-2099. [PMID: 19051019 DOI: 10.1007/s10620-008-0593-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
513 Cucchiara S, Latiano A, Palmieri O, Canani RB, D’Incà R, Guariso G, Vieni G, De Venuto D, Riegler G, De’Angelis GL. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:171-179. [PMID: 17255827 DOI: 10.1097/mpg.0b013e31802c41f3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
514 Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010;55:1413-1420. [PMID: 19533357 DOI: 10.1007/s10620-009-0856-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
515 Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis 2007;8:65-71. [PMID: 17532817 DOI: 10.1111/j.1443-9573.2007.00287.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
516 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 120] [Article Influence: 12.3] [Reference Citation Analysis]
517 Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. [PMID: 25228829 DOI: 10.3904/kjim.2014.29.5.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
518 Liao X, Zhao Z, Li H, Wu B, Huo J, Li L, Li X, Cao X, Xia M, Wang C, Bai C. Fullerene nanoparticles for the treatment of ulcerative colitis. Sci China Life Sci 2021. [PMID: 34735681 DOI: 10.1007/s11427-021-2001-0] [Reference Citation Analysis]
519 Picco MF. Everything old is new again? A fresh look at corticosteroids in ulcerative colitis. Am J Gastroenterol 2008;103:2517-8. [PMID: 18855853 DOI: 10.1111/j.1572-0241.2008.02112.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
520 Li Y, Tian Y, Yu C, Zhu W, Li J. A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease. Scand J Gastroenterol 2009;44:1435-42. [PMID: 19883269 DOI: 10.3109/00365520903367254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
521 Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007;26:313-29. [PMID: 17635367 DOI: 10.1111/j.1365-2036.2007.03379.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
522 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
523 Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panés J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13(15): 2193-2197 [PMID: 17465500 DOI: 10.3748/wjg.v13.i15.2193] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
524 Mahadevan U, Silverberg MS. Inflammatory Bowel Disease-Gastroenterology Diamond Jubilee Review. Gastroenterology. 2018;154:1555-1558. [PMID: 29550591 DOI: 10.1053/j.gastro.2017.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
525 Pandurangan AK, Mohebali N, Norhaizan ME, Looi CY. Gallic acid attenuates dextran sulfate sodium-induced experimental colitis in BALB/c mice. Drug Des Devel Ther 2015;9:3923-34. [PMID: 26251571 DOI: 10.2147/DDDT.S86345] [Cited by in Crossref: 58] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
526 Hicks CW, Wick EC, Salvatori R, Ha CY. Perioperative Corticosteroid Management for Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:221-8. [DOI: 10.1097/mib.0000000000000185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Chebli LA, Chaves LD, Pimentel FF, Guerra DM, Barros RM, Gaburri PD, Zanini A, Chebli JM. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-619. [PMID: 19705415 DOI: 10.1002/ibd.21083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
528 Reinisch W, Van Assche G, Befrits R, Connell W, D'haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. Journal of Crohn's and Colitis 2012;6:248-58. [DOI: 10.1016/j.crohns.2011.11.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
529 Bernal I, Mañosa M, Domènech E, Garcia-Planella E, Navarro M, Lorenzo-Zúñiga V, Cabré E, Gassull MA. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006;51:1434-8. [PMID: 16868820 DOI: 10.1007/s10620-006-9103-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
530 Oliva-hemker M, Escher J, Moore D, Dubinksy M, Hildebrand H, Koda Y, Murch S, Sandhu B, Seo J, Tanzi M, Warner B. Refractory Inflammatory Bowel Disease in Children. Journal of Pediatric Gastroenterology & Nutrition 2008;47:266-72. [DOI: 10.1097/mpg.0b013e318181b48c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
531 Lazebnik LB, Lychkova AE, Knyazev OV. Treatment of experimental ulcerative colitis. Bull Exp Biol Med 2012;153:889-92. [PMID: 23113311 DOI: 10.1007/s10517-012-1852-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
532 Iudicibus SD, Lucafò M, Martelossi S, Pierobon C, Ventura A, Decorti G. MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World J Gastroenterol 2013; 19(44): 7947-7954 [PMID: 24307788 DOI: 10.3748/wjg.v19.i44.7947] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
533 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 20.8] [Reference Citation Analysis]
534 Christophorou D, Funakoshi N, Duny Y, Valats J, Bismuth M, Pineton De Chambrun G, Daures J, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12. [DOI: 10.1111/apt.13102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
535 de Saussure P, Lavergne-Slove A, Mazeron MC, Alain S, Matuchansky C, Bouhnik Y. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:1323-1327. [PMID: 15606394 DOI: 10.1111/j.1365-2036.2004.02273.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
536 Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16 Suppl 1:S1-S11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
537 Duszka K, Wahli W. Enteric Microbiota⁻Gut⁻Brain Axis from the Perspective of Nuclear Receptors. Int J Mol Sci 2018;19:E2210. [PMID: 30060580 DOI: 10.3390/ijms19082210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
538 Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283-294. [PMID: 24363029 DOI: 10.1007/s00535-013-0922-y] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 9.6] [Reference Citation Analysis]
539 Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, Chan FK. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther. 2009;29:843-854. [PMID: 19154567 DOI: 10.1111/j.1365-2036.2009.03944.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
540 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
541 Rizzello F, Praticò C, Calabrese C, Gionchetti P. Rescue therapy: ciclosporin or infliximab? Expert Review of Clinical Immunology 2014;9:503-5. [DOI: 10.1586/eci.13.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
542 Yamamoto T, Lightner AL, Spinelli A, Kotze PG. Perioperative management of ileocecal Crohn's disease in the current era. Expert Rev Gastroenterol Hepatol 2020;14:843-55. [PMID: 32729736 DOI: 10.1080/17474124.2020.1802245] [Reference Citation Analysis]
543 Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev Gastroenterol Hepatol 2009;3:407-15. [PMID: 19673627 DOI: 10.1586/egh.09.25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
544 Rosenfeld G, Parker CE, MacDonald JK, Bressler B. Etrolizumab for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;:CD011661. [PMID: 26630451 DOI: 10.1002/14651858.CD011661.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
545 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
546 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 17.8] [Reference Citation Analysis]
547 Baker AC, Green TL, Chew VW, Tung K, Amini A, Lim D, Cho K, Greenhalgh DG. Enhanced steroid response of a human glucocorticoid receptor splice variant. Shock. 2012;38:11-17. [PMID: 22706020 DOI: 10.1097/shk.0b013e318257c0c0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
548 Hanauer SB. Crohn's disease: step up or top down therapy. Best Practice & Research Clinical Gastroenterology 2003;17:131-7. [DOI: 10.1053/bega.2003.0361] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
549 Safroneeva E, Vavricka SR, Fournier N, Straumann A, Rogler G, Schoepfer AM. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2015;21:1348-1358. [PMID: 25806845 DOI: 10.1097/mib.0000000000000368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
550 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
551 Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am. 2012;41:443-462. [PMID: 22500528 DOI: 10.1016/j.gtc.2012.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
552 Saibeni S, Meucci G, Papi C, Manes G, Fascì-Spurio F. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame? Expert Rev Gastroenterol Hepatol 2014;8:949-62. [PMID: 24882015 DOI: 10.1586/17474124.2014.924396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
553 Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-2035. [PMID: 16128948 DOI: 10.1111/j.1572-0241.2005.50219.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
554 Zhang L, Wei X, Zhang R, Si D, Petitte JN, Ahmad B, Zhang M. A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendotoxin Effects. Int J Mol Sci 2019;20:E3974. [PMID: 31443263 DOI: 10.3390/ijms20163974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
555 Han W, Xu J, Hu N, Mei Q, Liu M. Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. Scandinavian Journal of Gastroenterology 2014;49:424-33. [DOI: 10.3109/00365521.2014.886716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
556 Lee H, Cleynen I. Molecular Profiling of IBD Subtypes and Therapy Responses. In: Hedin C, Rioux JD, D'amato M, editors. Molecular Genetics of Inflammatory Bowel Disease. Cham: Springer International Publishing; 2019. pp. 157-82. [DOI: 10.1007/978-3-030-28703-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
557 Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice: . Inflammatory Bowel Diseases 2006;12:29-32. [DOI: 10.1097/01.mib.0000192323.82426.83] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
558 Subramanian V, Saxena S, Kang J, Pollok RCG. Preoperative Steroid Use and Risk of Postoperative Complications in Patients With Inflammatory Bowel Disease Undergoing Abdominal Surgery. The American Journal of Gastroenterology 2008;103:2373-81. [DOI: 10.1111/j.1572-0241.2008.01942.x] [Cited by in Crossref: 137] [Cited by in F6Publishing: 113] [Article Influence: 9.8] [Reference Citation Analysis]
559 Bruining DH, Loftus EV Jr. Crohn's disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know. Abdom Imaging 2009;34:297-302. [PMID: 18493815 DOI: 10.1007/s00261-008-9410-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
560 Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci. 2010;55:2002-2007. [PMID: 19937467 DOI: 10.1007/s10620-009-0962-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
561 Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46:135-139. [PMID: 24246151 DOI: 10.1016/j.dld.2013.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
562 Steinberg JM, Charabaty A. The Management Approach to the Adolescent IBD Patient: Health Maintenance and Medication Considerations. Curr Gastroenterol Rep 2020;22:5. [PMID: 31997099 DOI: 10.1007/s11894-019-0739-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
563 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
564 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
565 Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohns Colitis. 2011;5:1-4. [PMID: 21272796 DOI: 10.1016/j.crohns.2010.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
566 Setoyama H, Ido A, Numata M, Moriuchi A, Yamaji N, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. Life Sci 2011;89:269-75. [PMID: 21763320 DOI: 10.1016/j.lfs.2011.06.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
567 Williams EL, Stimpson ML, Collins PL, Enki DG, Sinha A, Lee RW, Dhanda AD. Development and validation of a novel bioassay to determine glucocorticoid sensitivity. Biomark Res 2016;4:26. [PMID: 27999674 DOI: 10.1186/s40364-016-0079-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
568 Wung PK, Anderson T, Fontaine KR, Hoffman GS, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Stone JH; WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL RESEARCH GROUP. Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum 2008;59:746-53. [PMID: 18438908 DOI: 10.1002/art.23561] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
569 Yang L, Dou H, Song Y, Hou Y. Benzenediamine analog FC-99 inhibits TLR2 and TLR4 signaling in peritoneal macrophage in vitro. Life Sciences 2016;144:129-37. [DOI: 10.1016/j.lfs.2015.11.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
570 Zhu Q, Cao Q, Si JM. Quality of care for patients with inflammatory bowel disease in East China. World J Gastroenterol 2008; 14(4): 612-616 [PMID: 18203296 DOI: 10.3748/wjg.14.612] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
571 Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc 2009;69:1299-310. [PMID: 19249771 DOI: 10.1016/j.gie.2008.08.042] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
572 Mantzaris GJ, Roussos A, Christidou A, Koilakou S, Kalantzis CN, Petraki K, Sfakianakis M, Karagiannidis A, Polyzou P. The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn's disease. J Crohns Colitis 2007;1:28-34. [PMID: 21172181 DOI: 10.1016/j.crohns.2007.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
573 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
574 Islam J, Sato S, Watanabe K, Watanabe T, Ardiansyah, Hirahara K, Aoyama Y, Tomita S, Aso H, Komai M, Shirakawa H. Dietary tryptophan alleviates dextran sodium sulfate-induced colitis through aryl hydrocarbon receptor in mice. J Nutr Biochem 2017;42:43-50. [PMID: 28113104 DOI: 10.1016/j.jnutbio.2016.12.019] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 15.4] [Reference Citation Analysis]
575 Ibrahim A, Dahlqvist P, Olsson T, Lundgren D, Werner M, Suhr OB, Karling P. The clinical course after glucocorticoid treatment in patients with inflammatory bowel disease is linked to suppression of the hypothalamic-pituitary-adrenal axis: a retrospective observational study. Therap Adv Gastroenterol 2017;10:829-36. [PMID: 29147134 DOI: 10.1177/1756283X17730748] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
576 Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012;6:160-173. [PMID: 22325170 DOI: 10.1111/j.1365-2036.2011.04717.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
577 Markowitz J. The Natural History of Pediatric Crohn Disease. In: Mamula P, Markowitz JE, Baldassano RN, editors. Pediatric Inflammatory Bowel Disease. Boston: Springer US; 2008. pp. 67-74. [DOI: 10.1007/978-0-387-73481-1_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
578 Zhou YL, Xie S, Wang P, Zhang T, Lin MY, Tan JS, Zhi FC, Jiang B, Chen Y. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China. J Dig Dis 2014;15:483-90. [PMID: 24828856 DOI: 10.1111/1751-2980.12161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
579 Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606-1619. [PMID: 22914296 DOI: 10.1016/s0140-6736(12)60150-0] [Cited by in Crossref: 840] [Cited by in F6Publishing: 408] [Article Influence: 84.0] [Reference Citation Analysis]
580 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 562] [Article Influence: 39.3] [Reference Citation Analysis]
581 Barrett TA. Developmental biology. Intestinal wound healing requires a Wnt balancing act. Science 2012;338:51-2. [PMID: 23042874 DOI: 10.1126/science.1229414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
582 Ho G, Lees C, Satsangi J. Pharmacogenetics and Inflammatory Bowel Disease: Progress and Prospects. Inflammatory Bowel Diseases 2004;10:148-58. [DOI: 10.1097/00054725-200403000-00014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
583 Lenti MV, Mengoli C, Vernero M, Aronico N, Conti L, Borrelli de Andreis F, Cococcia S, Di Sabatino A. Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease. Front Immunol 2020;11:485. [PMID: 32269571 DOI: 10.3389/fimmu.2020.00485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
584 D'haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. The Lancet 2008;371:660-7. [DOI: 10.1016/s0140-6736(08)60304-9] [Cited by in Crossref: 845] [Cited by in F6Publishing: 252] [Article Influence: 60.4] [Reference Citation Analysis]
585 Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009;3:271-6. [PMID: 21172286 DOI: 10.1016/j.crohns.2009.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
586 Vecchi Brumatti L, Marcuzzi A, Tricarico PM, Zanin V, Girardelli M, Bianco AM. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules. 2014;19:21127-21153. [PMID: 25521115 DOI: 10.3390/molecules191221127] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 8.8] [Reference Citation Analysis]
587 Latiano A, Palmieri O, Latiano T, Corritore G, Bossa F, Martino G, Biscaglia G, Scimeca D, Valvano MR, Pastore M. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One. 2011;6:e22688. [PMID: 21818367 DOI: 10.1371/journal.pone.0022688] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
588 Gabbani T, Manetti N, Bagnoli S, Annese V. Beclomethasone dipropionate for the treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2014;3:87-96. [DOI: 10.1517/21678707.2014.968125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
589 Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010;4:1-14. [PMID: 20479907 DOI: 10.5009/gnl.2010.4.1.1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
590 Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0212989. [PMID: 30807613 DOI: 10.1371/journal.pone.0212989] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
591 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
592 Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol. 2009;21:1-8. [PMID: 19011573 DOI: 10.1097/MEG.0b013e32830bfb88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
593 Kinnier CV, Asare EA, Mohanty S, Paruch JL, Rajaram R, Bilimoria KY. Risk prediction tools in surgical oncology. J Surg Oncol 2014;110:500-8. [PMID: 24975865 DOI: 10.1002/jso.23714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
594 Reardon C. Neuro-immune interactions in the cholinergic anti-inflammatory reflex. Immunol Lett 2016;178:92-6. [PMID: 27542331 DOI: 10.1016/j.imlet.2016.08.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
595 Shapiro JM, Hagin SE, Shah SA, Bright R, Law M, Moniz H, Giacalone J, Jackvony T, Taleban S, Samad Z. Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. Dig Dis Sci. 2016;61:1635-1640. [PMID: 26725063 DOI: 10.1007/s10620-015-4010-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
596 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
597 Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:60-65. [PMID: 15352896 DOI: 10.1111/j.1365-2036.2004.02048.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
598 Damsker JM, Conklin LS, Sadri S, Dillingham BC, Panchapakesan K, Heier CR, McCall JM, Sandler AD. VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis. Inflamm Res 2016;65:737-43. [PMID: 27261270 DOI: 10.1007/s00011-016-0956-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
599 Pedersen N, Duricova D, Lenicek M, Elkjaer M, Bortlik M, Andersen PS, Vitek L, Davidsen B, Wewer V, Lukas M, Munkholm P. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. Eur J Gastroenterol Hepatol 2010;22:1196-203. [PMID: 20739896 DOI: 10.1097/MEG.0b013e32833dde2e] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
600 Deng Q, Tan G, Deng F, Zhi F. Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric α-defensins in IBD Patients. J Clin Gastroenterol 2020;54:e50-5. [PMID: 31403980 DOI: 10.1097/MCG.0000000000001146] [Reference Citation Analysis]
601 Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn’s disease. Gastroenterology 2003;125:906-10. [DOI: 10.1016/s0016-5085(03)01129-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
602 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
603 Manohar M, Marzinke MA. Application of Chromatography Combined With Mass Spectrometry in Therapeutic Drug Monitoring. Clinical Challenges in Therapeutic Drug Monitoring. Elsevier; 2016. pp. 45-70. [DOI: 10.1016/b978-0-12-802025-8.00003-9] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
604 Ramakrishna BS, Makharia GK, Abraham P, Ghoshal UC, Jayanthi V, Agarwal BK, Ahuja V, Bhasin DK, Bhatia SJ, Choudhuri G. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian J Gastroenterol. 2012;31:307-323. [PMID: 23096266 DOI: 10.1007/s12664-012-0259-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
605 Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohnʼs Disease: . American Journal of Gastroenterology 2009;104:3042-9. [DOI: 10.1038/ajg.2009.493] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 6.3] [Reference Citation Analysis]
606 Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn’s disease with certolizumab pegol. Expert Review of Clinical Immunology 2014;3:683-94. [DOI: 10.1586/1744666x.3.5.683] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
607 Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, The Ibsen Study Group. Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN study). Scandinavian Journal of Gastroenterology 2009;42:602-10. [DOI: 10.1080/00365520601076124] [Cited by in Crossref: 138] [Cited by in F6Publishing: 111] [Article Influence: 10.6] [Reference Citation Analysis]
608 Huang Z, Chao K, Li M, Zhi M, Tang J, Hu P, Gao X. Methotrexate for Refractory Crohn's Disease Compared with Thiopurines: A Retrospective Non-head-to-head Controlled Study. Inflamm Bowel Dis 2017;23:440-7. [PMID: 28129286 DOI: 10.1097/MIB.0000000000001022] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
609 Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-136. [PMID: 23121200 DOI: 10.1111/apt.12118] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
610 Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006893. [PMID: 18254120 DOI: 10.1002/14651858.cd006893] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 5.0] [Reference Citation Analysis]
611 Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23:395-399. [PMID: 17545775 DOI: 10.1097/mog.0b013e32815b601b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
612 Randall C, Vizuete J, Wendorf G, Ayyar B, Constantine G. Current and emerging strategies in the management of Crohn's disease. Best Pract Res Clin Gastroenterol 2012;26:601-10. [PMID: 23384805 DOI: 10.1016/j.bpg.2012.11.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
613 Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflamm Bowel Dis 2020;26:941-8. [PMID: 31560046 DOI: 10.1093/ibd/izz204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
614 Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374-381. [PMID: 24961751 DOI: 10.1111/apt.12834] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
615 Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:319-34, x. [PMID: 15177541 DOI: 10.1016/j.gtc.2004.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
616 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
617 Balbas-Martinez V, Ruiz-Cerdá L, Irurzun-Arana I, González-García I, Vermeulen A, Gómez-Mantilla JD, Trocóniz IF. A systems pharmacology model for inflammatory bowel disease. PLoS One 2018;13:e0192949. [PMID: 29513758 DOI: 10.1371/journal.pone.0192949] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
618 Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis 2004;10 Suppl 2:S11-21. [PMID: 15475769 DOI: 10.1097/00054725-200407002-00003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
619 Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Early versus late surgery in patients with intestinal Behçet disease. Dis Colon Rectum. 2012;55:65-71. [PMID: 22156869 DOI: 10.1097/DCR.0b013e318238b57e] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
620 Khan N, Abbas AM, Moehlen M, Balart L. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel Dis. 2013;19:1379-1383. [PMID: 23542534 DOI: 10.1097/mib.0b013e31828133e8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
621 Katz S. Update in medical therapy of ulcerative colitis: a practical approach. J Clin Gastroenterol. 2002;34:397-407. [PMID: 11907350 DOI: 10.1097/00004836-200204000-00004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
622 Patil SA, Flasar MH, Lin J, Lingohr-Smith M, Skup M, Wang S, Chao J, Cross RK. Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. Dig Dis Sci 2019;64:60-7. [PMID: 30311154 DOI: 10.1007/s10620-018-5322-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
623 Nishida Y, Hosomi S, Watanabe K, Watanabe K, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol 2018;53:579-85. [PMID: 29171305 DOI: 10.1080/00365521.2017.1403647] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
624 Egan LJ, Sandborn WJ. Advances in the treatment of Crohn’s disease. Gastroenterology. 2004;126:1574-1581. [PMID: 15168368 DOI: 10.1053/j.gastro.2004.01.062] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
625 Duricova D, Pedersen N, Lenicek M, Jakobsen C, Lukas M, Wewer V, Munkholm P. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: A review. Journal of Crohn's and Colitis 2011;5:81-90. [DOI: 10.1016/j.crohns.2010.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
626 Sidoroff M, Kolho K. Glucocorticoid sensitivity in inflammatory bowel disease. Annals of Medicine 2012;44:578-87. [DOI: 10.3109/07853890.2011.590521] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
627 Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin Immunol. 2009;132:1-9. [PMID: 19321388 DOI: 10.1016/j.clim.2009.02.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
628 Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008;28:221-7. [PMID: 18485127 DOI: 10.1111/j.1365-2036.2008.03734.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
629 Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:1070-1075. [PMID: 17627901 DOI: 10.1016/j.cgh.2007.04.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
630 Fell JM. Control of systemic and local inflammation with transforming growth factor beta containing formulas. JPEN J Parenter Enteral Nutr. 2005;29:S126-S128; discussion S129-133, S184-188. [PMID: 15980274 DOI: 10.1177/01486071050290s4s126] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
631 Schultheiß C, Weischenberg R, Herrmann A, Haller B, Schmid RM, Reindl W, Huber W. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. Artif Organs 2015;39:187-92. [PMID: 24981894 DOI: 10.1111/aor.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
632 Nishida Y, Hosomi S, Yamagami H, Sugita N, Itani S, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Watanabe T, Fujiwara Y. Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. PLoS One. 2019;14:e0213505. [PMID: 30845259 DOI: 10.1371/journal.pone.0213505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
633 Khan N, Patel D, Shah Y, Lichtenstein G, Yang Y. A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:991-7. [DOI: 10.1097/mib.0000000000001080] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
634 Klepsch V, Moschen AR, Tilg H, Baier G, Hermann-Kleiter N. Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD. Front Immunol 2019;10:1070. [PMID: 31139192 DOI: 10.3389/fimmu.2019.01070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
635 Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14:554-565. [PMID: 17973299 DOI: 10.1002/ibd.20301] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 5.7] [Reference Citation Analysis]
636 Schröder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006;18:11-6. [PMID: 16357613 DOI: 10.1097/00042737-200601000-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
637 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 574] [Article Influence: 65.7] [Reference Citation Analysis]
638 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
639 Yu Y, Chen KC, Chen J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis. World J Pediatr. 2019;15:26-36. [PMID: 30666565 DOI: 10.1007/s12519-018-0204-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
640 García-Bosch O, Aceituno M, Ordás I, Etchevers J, Sans M, Feu F, Panés J, Ricart E. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci 2016;61:2051-9. [PMID: 26921082 DOI: 10.1007/s10620-016-4089-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
641 Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn’s disease. Aliment Pharmacol Ther. 2003;17:1459-1464. [PMID: 12823147 DOI: 10.1046/j.1365-2036.2003.01590.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
642 Castro B, Crespo J, García-suárez C, Fábrega E, Casafont F, Pons-romero F. Triple terapia inmunosupresora en el tratamiento de la colitis ulcerosa grave. Gastroenterología y Hepatología 2004;27:1-5. [DOI: 10.1016/s0210-5705(03)70436-1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
643 Lightner AL, Shen B. Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". Gastroenterol Rep (Oxf) 2017;5:165-77. [PMID: 28852521 DOI: 10.1093/gastro/gow046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
644 Sparrow MP, Irving PM, Hanauer SB. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep 2009;11:496-503. [PMID: 19903426 DOI: 10.1007/s11894-009-0075-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
645 Wang M, Ramirez J, Han J, Jia Y, Domenico J, Seibold MA, Hagman JR, Gelfand EW. The steroidogenic enzyme Cyp11a1 is essential for development of peanut-induced intestinal anaphylaxis. J Allergy Clin Immunol 2013;132:1174-1183.e8. [PMID: 23870673 DOI: 10.1016/j.jaci.2013.05.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
646 Pugliese D, Aratari A, Festa S, Ferraro PM, Monterubbianesi R, Guidi L, Scribano ML, Papi C, Armuzzi A. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterol Res Pract 2018;2018:4195968. [PMID: 30402090 DOI: 10.1155/2018/4195968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
647 Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51:241-251. [PMID: 26162647 DOI: 10.1007/s00535-015-1102-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
648 Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
649 Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139:1147-1155. [PMID: 20637205 DOI: 10.1053/j.gastro.2010.06.070] [Cited by in Crossref: 388] [Cited by in F6Publishing: 347] [Article Influence: 32.3] [Reference Citation Analysis]
650 Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011;5:679-84. [PMID: 22017695 DOI: 10.1586/egh.11.81] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
651 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
652 Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41:874-888. [PMID: 18090155 DOI: 10.1097/mcg.0b013e3180479435] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
653 Guo W, Liu W, Jin B, Geng J, Li J, Ding H, Wu X, Xu Q, Sun Y, Gao J. Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation. Int Immunopharmacol. 2015;24:232-238. [PMID: 25523461 DOI: 10.1016/j.intimp.2014.12.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
654 Hanauer SB, Kirsner JB. Treat the Patient or Treat the Disease? Dig Dis 2012;30:400-3. [DOI: 10.1159/000338139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
655 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 30.1] [Reference Citation Analysis]
656 Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn’s disease. J Pediatr Gastroenterol Nutr. 2006;42:40-45. [PMID: 16385252 DOI: 10.1097/01.mpg.0000189137.06151.33] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
657 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
658 Khan N, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. World J Gastroenterol 2017; 23(45): 8008-8016 [PMID: 29259376 DOI: 10.3748/wjg.v23.i45.8008] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
659 MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2016;11:CD007572. [PMID: 27885650 DOI: 10.1002/14651858.CD007572.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
660 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
661 Iudicibus SD, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 2011; 17(9): 1095-1108 [PMID: 21448414 DOI: 10.3748/wjg.v17.i9.1095] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 68] [Article Influence: 6.9] [Reference Citation Analysis]
662 Kotze PG, Abou-Rejaile VR, Uiema LA, Olandoski M, Sartor MC, Miranda EF, Kotze LM, Saad-Hossne R. Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study. Arq Gastroenterol 2014;51:39-45. [PMID: 24760063 DOI: 10.1590/s0004-28032014000100009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
663 Kwapisz L, Jairath V, Khanna R, Feagan B. Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. Expert Opin Drug Metab Toxicol 2017;13:793-801. [PMID: 28612627 DOI: 10.1080/17425255.2017.1340454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
664 Gisbert JP, Gomollón F. Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2007;30:469-86. [DOI: 10.1157/13110491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
665 Roblin X, Serre-debeauvais F, Phelip J, Faucheron J, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B. 6-Tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005;21:829-39. [DOI: 10.1111/j.1365-2036.2005.02419.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
666 Yamagami H, Nishida Y, Nagami Y, Hosomi S, Yukawa T, Otani K, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Fujiwara Y. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis. Rom J Intern Med 2017;55:151-7. [PMID: 28222041 DOI: 10.1515/rjim-2017-0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
667 Jiao YF, Lu M, Zhao YP, Liu N, Niu YT, Niu Y, Zhou R, Yu JQ. N-Methylcytisine Ameliorates Dextran-Sulfate-Sodium-Induced Colitis in Mice by Inhibiting the Inflammatory Response. Molecules 2018;23:E510. [PMID: 29495327 DOI: 10.3390/molecules23030510] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
668 Raddatz D, Bockemühl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005;17:547-557. [PMID: 15827446 DOI: 10.1097/00042737-200505000-00012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.8] [Reference Citation Analysis]
669 Musch E, Lutfi T, von Stein P, Zargari A, Admyre C, Malek M, Löfberg R, von Stein OD. Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity: . Inflammatory Bowel Diseases 2013;19:283-92. [DOI: 10.1002/ibd.23019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
670 Dignass A, Marteau P. Mesalamine in the treatment of active Crohn’s disease. Gastroenterology 2005;128:245-6. [DOI: 10.1053/j.gastro.2004.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
671 Shergill AK, Terdiman JP. Controversies in the treatment of Crohn’s disease: The case for an accelerated step-up treatment approach. World J Gastroenterol 2008; 14(17): 2670-2677 [PMID: 18461652 DOI: 10.3748/wjg.14.2670] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
672 Lu Y, Kim NM, Jiang YW, Zhang H, Zheng D, Zhu FX, Liang R, Li B, Xu HX. Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. Br J Pharmacol 2018;175:1085-99. [PMID: 29352742 DOI: 10.1111/bph.14150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
673 Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 2005;39:557-69. [PMID: 16000921 DOI: 10.1097/01.mcg.0000170735.43887.3a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
674 Gionchetti P, Praticò C, Rizzello F, Calafiore A, Capozzi N, Campieri M, Calabrese C. The role of Budesonide-MMX in active ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;8:215-22. [DOI: 10.1586/17474124.2014.887437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
675 Aguas Peris M, Del Hoyo J, Bebia P, Faubel R, Barrios A, Bastida G, Valdivieso B, Nos P. Telemedicine in Inflammatory Bowel Disease: Opportunities and Approaches. Inflammatory Bowel Diseases 2015;21:392-9. [DOI: 10.1097/mib.0000000000000241] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 7.1] [Reference Citation Analysis]
676 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dos